

=> file medline cancerit scisearch biosis embase wpids uspatfull

(4) an expression or replicating vector comprising a nucleic acid as in (2), and

(5) a host cell comprising a vector as in (4).  
USE - "The \*\*\*312C2\*\*\* proteins are expressed in the thymus and are induced on T cells and spleen cells following activation. Engagement of \*\*\*312C2\*\*\* stimulates proliferation of T cells, clones, antigen-specific proliferation and cytokine production by T-cells, and potentiates T cell expansion or apoptosis.

The products can be used in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g. cancerous conditions or degenerative conditions. They can be used in the regulation or development of haematopoietic cells, e.g. lymphoid cells which affect immunological responses, e.g. autoimmune disorders.

In particular the products can be used to treat rheumatoid arthritis, systemic lupus erythematosus (SLE), Hashimoto's autoimmune thyroiditis, as well as acute and chronic inflammatory responses in which T cell activation, expansion, and/or immunological T cell memory play an important role. They can also be used in disorders in which abnormal T cell responses are of importance, e.g. in a transplantation rejection situation. They can be used to mediate T cell interactions with other cell types leading to, e.g. cell proliferation, enhanced cytokine synthesis by the cells and consequential amplification of T cell proliferation.

The products can also be used to redirect T cell responses, e.g. towards a Th0/Th1 pathway or towards a Th2 type response. The products can also be used for detection, diagnosis or drug screening.

Dwg.0/0

=> s t(t)cell or (t(w)lymphocyte or thymocyte

L2 397502 T(T) CELL OR T(W) LYMPHOCYTE OR THYMOCYTE

=> s receptor

L3 1875287 RECEPTOR

=> s co-stimulat?

L4 4810 CO-STIMULAT?

=> s i2 and i3 and i4

L5 1185 L2 AND L3 AND L4

=> s proliferat? or activat? or divisi? or growth

L6 5520103 PROLIFERAT? OR ACTIVAT? OR DIVID? OR GROWTH

=> s i5 and i6

L7 1080 L5 AND L6

=> s antigen(Ba)specif? or antigen(Ba)target?

L8 194581 ANTIGEN(BA) SPECIF? OR ANTIGEN(BA) TARGET?

=> s i7 and i8

L9 234 L7 AND L8

=> dup rem

ENTER L# LIST OR (END):19

PROCESSING COMPLETED FOR L9

L10 148 DUP REM L9 (86 DUPLICATES REMOVED)

=> s i10 and ((nucleic(w)acid or dna or cdna or gene or polynucleotide)(4)entodd?)

PATENT NO KIND APPLICATION DATE  
WO 9806842 A1 WO 97-JUS13891 970814  
AU 97-40556 A AU 97-40556 970814

FILING DETAILS:  
PATENT NO KIND PATENT NO  
AU 97-40556 A Based on WO 9806842  
PRIORITY APPLN INFO: US 96-27901 961007; US 96-689943 960816  
AU WO 9806842 A UPB: 980406  
Pure or recombinant \*\*\*312C2\*\*\* protein (A) or a conservatively modified variant is new.  
Also claimed are:  
(1) an antibody which specifically binds a protein as in (A);  
(2) an isolated or recombinant nucleic acid which encodes a protein or peptide;  
(3) a recombinant nucleic acid comprising a sequence having at least 70% identity over a stretch of at least 30 nucleotides to a \*\*\*312C2\*\*\* nucleic acid sequence as shown;

L11 ANSWER 1 OF 52 MEDLINE MEDLINE  
ACCESSION NUMBER: 97054641  
DOCUMENT NUMBER: 97054641  
TITLE: \*\*\*Antigen\*\*\* - \*\*\*specific\*\*\*  
- \*\*\*targeting\*\*\* of CD28-mediated T cell \*\*\*co\*\*\*  
- \*\*\*stimulation\*\*\* using chimeric single-chain antibody variable fragment-CD28 \*\*\*receptors\*\*\* .

AUTHOR: Alvarez-Yallina L; Hawkins R E  
CORPORATE SOURCE: Centre for Protein Engineering, MRC Centre, Cambridge, GB.  
SOURCE: EUROPEAN JOURNAL OF IMMUNOLOGY, (1996 Oct) 26 (10)  
2304-9.

Journal code: EN5 ISSN: 0014-2980.  
PUB. COUNTRY: GERMANY-Germany, Federal Republic of

Journal: Article (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority journals; Cancer journals

ENTRY MONTH: 1997/02/02

ENTRY WEEK: 1997/02/04

AB T cells require two distinct signals for optimal \*\*\*activation\*\*\*  
One is an \*\*\*antigen\*\*\* - \*\*\*specific\*\*\* signal and is provided by engagement of the T cell \*\*\*receptor\*\*\* (TCR). The second is an antigen-independent signal mediated by engagement of the T cell surface molecule CD28 with members of the B7 family. To endow CD28 molecules with an antibody-type recognition, we have constructed chimeric single-chain antibody variable fragment (scFv)-CD28 molecules; following transfection of the \*\*\*genes\*\*\* \*\*\*encoding\*\*\* such constructs into the Jurkat human T cell line we show that they are stably expressed as functional cell surface \*\*\*receptors\*\*\*. These chimeric molecules have no apparent negative effects on the expression and signaling ability of the wild-type CD28 and TCR/CD3 molecules. When combined with signaling via the TCR/CD3 complex, these \*\*\*antigen\*\*\* - \*\*\*specific\*\*\* scFv-CD28 chimeric molecules provide signals similar to those elicited by the cross-linking of the unmodified CD28 molecules. Furthermore, the generation of double transfectants simultaneously expressing scFv-CD28 and scFv-CD3 chimeras demonstrates that \*\*\*antigen\*\*\* - \*\*\*specific\*\*\* \*\*\*co\*\*\* - \*\*\*simulatory\*\*\* signals can also synergize with signals mediated through chimeric CD3 zeta chains to secrete maximal levels of interleukin-2. Overall, our results suggest that optimal, predefined \*\*\*antigen\*\*\* - \*\*\*activation\*\*\* - or T cells directed by the \*\*\*specific\*\*\* of the scFv should be possible.

L11 ANSWER 2 OF 52 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD  
ACCESSION NUMBER: 95-131352 [17] WPIDS  
DOC. NO. NON-CP: N95-103169  
DOC. NO. CP: C95-050672  
TITLE: Novel \*\*\*CDNA\*\*\* \*\*\*encoding\*\*\* human \*\*\*receptor\*\*\* protein H4-1BB - useful to produce the protein which is used to treat auto immune disease and facilitate organ transplantation.  
DERVENT CLASS: 804 D16 S03  
INVENTOR(S): KWON, B S  
PATENT ASSIGNEE(S): (INDV) UNIV INDIANA FOUND  
COUNTRY COUNT: 34  
PATENT INFORMATION:

WO 9806842 A1 980219 (98/4)\* EN 71  
RW. AT BE CH DE DK EA ES F1 FR GB GH GR IE IT KE LS LU MC MW  
NL OA PT SD SE SZ UG ZW  
W. AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR  
TJ LC LM TR TT UA UZ VN YU  
AU 97-40556 A 980306 (98/3)

PATENT NO KIND APPLICATION DATE  
WO 9806842 A1 WO 97-JUS13891 970814  
AU 97-40556 A AU 97-40556 970814

FILING DETAILS:

PATENT NO KIND PATENT NO  
AU 97-40556 A Based on WO 9806842  
PRIORITY APPLN INFO: US 96-27901 961007; US 96-689943 960816  
AU WO 9806842 A UPB: 980406  
Pure or recombinant \*\*\*312C2\*\*\* protein (A) or a conservatively modified variant is new.  
Also claimed are:  
(1) an antibody which specifically binds a protein as in (A);  
(2) an isolated or recombinant nucleic acid which encodes a protein or peptide;  
(3) a recombinant nucleic acid comprising a sequence having at least 70% identity over a stretch of at least 30 nucleotides to a \*\*\*312C2\*\*\* nucleic acid sequence as shown;

APPLICATION DETAILS:  
PATENT NO KIND APPLICATION DATE  
WO 9806842 A1 980219 (98/4)\* EN 36  
RW. AT BE CH DE DK ES F1 FR GB GR IE IT LU MC NL PT SE  
W. AT BE DK ES FR GB GR IE IT LU MC NL PT SE  
NZ RU SE SI SK UA EP 719329 A 950403 (95/2)  
EP 719329 A 950703 (96/31) EN  
R. AT BE DK ES FR GB GR IE IT LU MC NL PT SE  
JP 05603911 W 970422 (97/26) 35  
NZ 273838 A 970922 (97/45)

PATENT NO KIND APPLICATION DATE

**FILING DETAILS:**

PATENT NO	KIND	PATENT NO
WO 9507984 A1	AU 94-77294 A	WO 94-US10457 940915
EP 719329 A1	AU 94-77294	EP 94-928141 940915
JP 09503911 W	WO 94-US10457	JP 94-90915
NZ 273838 A	JP 95-509364	WO 94-90915
	NZ 94-273838	WO 94-US10457 940915

**EXEMPLARY CLAIM:**

1 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)

LINE COUNT: 1523

AB A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a prokaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is trans-formed to produce interleukin-2.

**L11 ANSWER 4 OF 52 USPATFULL**

ACCESSION NUMBER: 1998-98795 USPATFULL

TITLE: \*\*\*Gene\*\*\* \*\*\*encoding\*\*\* interleukin-2 polypeptide, recombinant \*\*\*DNA\*\*\* carrying the gene, a living cell line possessing the recombinant DNA and method for producing interleukin-2 using the cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan Muramatsu, Masami, Tokorozawa, Japan Sugano, Haruo, Tokyo, Japan Matsui, Hiroshi, Yokohama, Japan Kishima, Nobukazu, Yokohama, Japan (non-U.S. corporation)

PRIORITY APPLN. INFO: US 93-122796 930916

AB A \*\*\*cDNA\*\*\* (1) \*\*\*encoding\*\*\* for human \*\*\*receptor\*\*\* protein H4-1BB is new.

USE - The use of H4-1BB to block H4-1BB ligand (H4-1BBL) finding has practical application in the suppression of the immune system during organ transplantation. The MAb against H4-1BB can be used to enhance T-cell \*\*\*proliferation\*\*\* by treating T-cells that have expressed \*\*\*receptor\*\*\* protein H4-1BB with the anti-H4-1BB MAb. Tumours transfected with H4-1BBL may be capable of delivering \*\*\*antigen\*\*\* \*\*\*specific\*\*\* signals as well as the \*\*\*co - \*\*\*stimulatory\*\*\* signals and can be killed by human cytotoxic \*\*\*T\*\*\* lymphocytes \*\*\*.

Dwg 0/5

**L11 ANSWER 3 OF 52 USPATFULL**

ACCESSION NUMBER: 1998-98302 USPATFULL

TITLE: Gene coded for interleukin-2 polypeptide recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan Muramatsu, Masami, Tokorozawa, Japan Sugano, Haruo, Tokyo, Japan Matsui, Hiroshi, Yokohama, Japan Kishima, Nobukazu, Yokohama, Japan Hanuro, Junji, Yokohama, Japan (non-U.S. corporation)

PRIORITY INFORMATION: JP 92-51122 820331

NUMBER DATE

PATENT INFORMATION: US 5795777 980818

APPLICATION INFO.: US 96-21097 980322 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 95-516563, filed on 18 Aug 1995 which is a continuation of Ser. No.

18 Jul 1994, filed on 26 Dec 1991, now patented. Pat. No. US 5620858 which is a continuation of Ser. No. US 89-322364, filed on 3 Apr 1989, now abandoned which is a continuation of Ser. No. US 87-26309, filed on 7 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-46346, filed on 3 Feb 1983, now patented. Pat. No. US 4738927

NUMBER DATE

PATENT INFORMATION: JP 82-82509 820518

APPLICATION INFO.: JP 82-219518 821215

RELATED APPLN. INFO.: JP 82-234607 821224

NUMBER DATE

PATENT INFORMATION: JP 82-230371 821229

APPLICATION INFO.: JP 82-82509 820518

RELATED APPLN. INFO.: JP 82-219518 821215

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-234607 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

**EXEMPLARY CLAIM:**

1 LINE COUNT: 1440

AB A novel secreted protein, BA3.1 is disclosed. Polynucleotides encoding BA3.1 are also provided.

**L11 ANSWER 6 OF 52 USPATFULL**

ACCESSION NUMBER: 1998-98344 USPATFULL

TITLE: Secreted proteins and polynucleotides encoding them

INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States McCoy, John M., Reading, MA, United States Lavallie, Edward R., Tewksbury, MA, United States Racine, Lisa A., Acton, MA, United States Menberg, David, Acton, MA, United States Tracy, Maurice, Chestnut Hill, MA, United States Spaulding, Vicki, Billerica, MA, United States Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5786465 980728

APPLICATION INFO.: US 96-721489 9605927 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 96-686878, filed on 26 Jul 1996

NUMBER DATE

PATENT INFORMATION: US 5795769 980818

APPLICATION INFO.: US 95-516563 950818 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 91-814049, filed on 26 Dec 1991, now patented. Pat. No. US 5260868 which is a continuation of Ser. No. US 89-332364, filed on 3 Apr 1989, now abandoned which is a continuation of Ser. No. US 87-26309, filed on 7 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-46346, filed on 3 Feb 1983, now patented. Pat. No. US 4738927

NUMBER DATE

PATENT INFORMATION: JP 92-51122 820331

APPLICATION INFO.: JP 82-82509 820518

RELATED APPLN. INFO.: JP 82-219518 821215

NUMBER DATE

PATENT INFORMATION: JP 82-229619 821224

APPLICATION INFO.: JP 82-234607 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

**EXEMPLARY CLAIM:**

1 LINE COUNT: 1440

AB A novel secreted protein, BA3.1 is disclosed. Polynucleotides encoding BA3.1 are also provided.

**L11 ANSWER 7 OF 52 USPATFULL**

ACCESSION NUMBER: 1998-75403 USPATFULL

TITLE: MYPPY variants of CTLA4 and uses thereof

INVENTOR(S): Kaufman, Claire M., DasRosier, Thomas J.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Walsh, Stephen

ASSISTANT EXAMINER: Karifman, Claire M.

LEGAL REPRESENTATIVE: Brown, Scott A.; DasRosier, Thomas J.

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5786465 980728

APPLICATION INFO.: US 95-505058 950721 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-228208, filed on 22 Jan 1993

NUMBER DATE

PATENT INFORMATION: US 5795769 980818

APPLICATION INFO.: US 95-516563 950818 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 91-814049, filed on 26 Dec 1991, now patented. Pat. No. US 5260868 which is a continuation of Ser. No. US 89-332364, filed on 3 Apr 1989, now abandoned which is a continuation of Ser. No. US 87-26309, filed on 7 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-46346, filed on 3 Feb 1983, now patented. Pat. No. US 4738927

NUMBER DATE

PATENT INFORMATION: JP 92-51122 820331

APPLICATION INFO.: JP 82-82509 820518

RELATED APPLN. INFO.: JP 82-219518 821215

NUMBER DATE

PATENT INFORMATION: JP 82-229619 821224

APPLICATION INFO.: JP 82-234607 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

PATENT INFORMATION: JP 82-51122 820331

APPLICATION INFO.: JP 82-229619 821224

RELATED APPLN. INFO.: JP 82-230371 821229

NUMBER DATE

also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/U.S. corporation)

interest from both uncomplexed MHC molecules and other endogenous MHC-peptide bound complexes.

SEARCHED  SERIALIZED  INDEXED  COPIED  OMBUDSMAN  COMPUTER SEARCHED  COMPUTER SERIALIZED  COMPUTER INDEXED  COMPUTER COPIED

NUMBER OF CLAIMS \_\_\_\_\_

PATENT INFORMATION: US 5773218 980530  
APPLICATION INFO.: US 95-482882 950607 (8)  
RELATED APPN INFO.: Division of Ser. No. US 94-286754, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 93-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-9266, filed on 22 Jan 1993, now abandoned and Ser. No. US 92-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now abandoned

L11 ANSWER 10 OF 52 USPATFULL  
ACCESSION NUMBER: 1998-61171 USPATFULL  
TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines  
INVENTOR(S): Ladd, Alma Elfin, Brooklyn, NY, United States  
Wang, Chang Yi, Cold Spring Harbor, NY, United States  
Zamb, Timothy Joseph, Stony Brook, NY, United States  
PATENT ASSIGNEE(S): United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)

L11 ANSWER 12 OF 52 USPATFULL  
ACCESSION NUMBER: 1998-61171 USPATFULL  
TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines  
INVENTOR(S): Wang, Chang Yi, Cold Spring Harbor, NY, United States  
Zamb, Timothy Joseph, Stony Brook, NY, United States  
PATENT ASSIGNEE(S): United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)

ANSWER 9 OF 52 USPATFULL  
1988-72709 USPATFULL  
ICAM-related protein fragments  
Gatlin, W. Michael, Seattle, WA, United States  
Vazeau, Rosemary, Seattle, WA, United States  
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States  
(U.S. corporation)  
PRIMARY EXAMINER: Draper, Gamette D.  
LEGAL REPRESENTATIVE: Anderson, Kathryn A.; Wight, Christopher L.  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 21 Drawing Page(s)  
LINE COUNT: 2658  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NUMBER	DATE
PATENT INFORMATION: US 5770586 980623	
APPLICATION INFO.: US 95-474368 950607 (8)	
RELATED APPLN INFO.: Division of Ser. No. US 95-425870, filed on 20 Apr 1995, now abandoned which is a continuation of Ser. No. US 93-102452, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-9256, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now abandoned	20
NUMBER	DATE

Blackburn, Robert P.

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Waish, Stephen

ASSISTANT EXAMINER: Kaufman, Claire M.

LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.;

NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 2155  
CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a cell-mediated immune system disease in a patient or to induce \*\*\*antigen\*\*\* - \*\*\*specific\*\*\* tolerance.

The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.

L11 ANSWER 14 OF 52 USPATFULL

ACCESSION NUMBER: 1998-308/1 USPATFULL

TITLE: Induction of \*\*\*antigen\*\*\* \*\*\*specific\*\*\*

INVENTOR(S): Kast, Wybe M., Leiden, Netherlands

RENT ASSIGNEE(S): Rijksuniversiteit Leiden, Leiden, Netherlands

(non-U.S. corporation)

Seed Capital Investments (SCI) B.V., Utrecht, Netherlands (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5731160 980324

APPLICATION INFO.: US 92-888943 920526 (7)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Caputa, Anthony C.

LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Figure(s); 9 Drawing Page(s)

LINE COUNT: 1222  
CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB Induction of an \*\*\*antigen\*\*\* - \*\*\*specific\*\*\*

\*\*\*lymphocyte\*\*\* response in a \*\*\*T\*\*\* - \*\*\*lymphocyte\*\*\*

culture, e.g. a primary cytotoxic \*\*\*T\*\*\* - \*\*\*lymphocyte\*\*\*

(CTL) response, by loading antigen-presenting vehicles which carry

empty MHC molecules with an antigen-derived T-cell-immunogenic

MHC-binding peptide, culturing

in the presence of the peptide-loaded \*\*\*antigen\*\*\* - presenting

vehicles under \*\*\*specific\*\*\* conditions. Optionally, an \*\*\*antigen\*\*\* -

\*\*\*specific\*\*\* - \*\*\*lymphocyte\*\*\* is isolated from

the resulting culture and cultured. The process can be used for

preparing CTL which are \*\*\*specific\*\*\* for viral or other

foreign \*\*\*antigens\*\*\*, or CTL which are \*\*\*specific\*\*\*

for autologous peptides. The process can also be used for the

identification of peptides that are capable of binding to MHC and

inducing a T cell response.

L11 ANSWER 15 OF 52 USPATFULL

ACCESSION NUMBER: 1998-28196 USPATFULL

TITLE: Secreted proteins and polynucleotides encoding

INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States

McCoy, John M., Reading, MA, United States

Lavallie, Edward R., Tewksbury, MA, United States

Racie, Lisa A., Acton, MA, United States

Menberg, David, Acton, MA, United States

Treacy, Maureen, Chestnut Hill, MA, United States

Saulding, Vicki, Billerica, MA, United States

Gentech Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5723315 980303

APPLICATION INFO.: US 96-702344 960823 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Waish, Stephen

ASSISTANT EXAMINER: Kaufman, Claire M.

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 32 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 1941

AB A transgenic animal, whose germ cells and somatic cells contain a transgene including a \*\*\*DNA\*\*\* sequence \*\*\*encoding\*\*\* a

DeRosier, Thomas J.

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kaufman, Claire M.

LEGAL REPRESENTATIVE: Brown, Scott A.; DeRosier, Thomas J.

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

LINE COUNT: 2437

CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L11 ANSWER 18 OF 52 USPATFULL

ACCESSION NUMBER: 1998-21893 USPATFULL

TITLE: Compositions and methods for use of IL-12 as an

adjuvant

INVENTOR(S): Scott, Phillip, Swarthmore, PA, United States

Trinchieri, Giorgio, Wynnewood, PA, United States

The Trustees of the University of Pennsylvania,

Philadelphia, PA, United States (U.S. corporation)

The Wistar Institute of Anatomy & Biology,

Philadelphia, PA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5723127 980303

APPLICATION INFO.: US 96-621433 960325 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 94-265087, filed on 17

Jun 1994, now patented. Pat. No. US 5571515 which

is a continuation-in-part of Ser. No. US

94-229282, filed on 18 Apr 1994, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Smith, Lynette F.

LEGAL REPRESENTATIVE: Howson and Howson

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1253

CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB Improved vaccine compositions and methods of making same are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvant amount of interleukin-12.

These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.

L11 ANSWER 19 OF 52 USPATFULL

ACCESSION NUMBER: 1998-17059 USPATFULL

TITLE: Transgenic animal model for autoimmune diseases

INVENTOR(S): Hanian, David M., Potomac, MD, United States

June, Carl H., Rockville, MD, United States

the Secretary of the Navy, Washington, DC, United States (U.S. government)

NUMBER DATE

PATENT INFORMATION: US 5719983 980217

APPLICATION INFO.: US 94-197790 940217 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 93-48042,

filed on 14 Apr 1993, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Campbell, Bruce R.

LEGAL REPRESENTATIVE: Spevak, A. David; Mandragoras, Amy E. Lahive

& Cockfield, LLP

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 32 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 1941

AB A transgenic animal, whose germ cells and somatic cells contain a

transgene including a \*\*\*DNA\*\*\* sequence \*\*\*encoding\*\*\* a

CD28 ligand and a tissue-specific promoter operably linked to the DNA sequence, wherein the tissue-specific promoter effects expression of the CD28 ligand in cells of a specific tissue of the animal is disclosed. This animal serves as a transgenic model for specific autoimmune diseases.

#### L11 ANSWER 20 OF 52 USPATFULL

ACCESSION NUMBER: 198514915 USPATFULL  
TITLE: Interleukin-4 "receptors"\*\*

INVENTOR(S): Mosley, Bruce; Seattle, WA, United States  
Backmann, M; Patricia; Poulsbo, WA, United States  
March, Carl J.; Seattle, WA, United States  
Idzardza, Rejane; Seattle, WA, United States  
PATENT ASSIGNEE(S): Immunex Corporation; Seattle, WA, United States (U.S. corporation)

#### NUMBER DATE

PATENT INFORMATION: US 5717072 980210  
APPLICATION INFO.: US 95-445169 950605 (8)  
RELATED APPLN. INFO.: Division of Ser. No. US 93-94669, filed on 20 Jul 1993, now patented. Pat. No. US 5593905 which is a division of Ser. No. US 90-480634, filed on 14 Feb 1989, which is a continuation-in-part of Ser. No. US 85-370524, filed on 23 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 85-326156, filed on 20 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-319438, filed on 2 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 88-265047, filed on 31 Oct 1988, now abandoned.

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Eisenschenk, Frank C.  
ASSISTANT EXAMINER: Davis, William J.  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 22 Drawing Page(s)  
LINE COUNT: 2563  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian antibodies that are immunoreactive with Interleukin-4 "receptor"\*\* proteins, \*\*\*DNAs\*\*\* and expression vectors encoding \*\*\*mammalian IL-4 "receptors"\*\*, and processes for producing mammalian IL-4 "receptors"\*\* as products of cell culture, as well as antibodies that are immunoreactive with IL-4 "receptors"\*\*. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, involves administering an effective amount of soluble IL-4 "receptor"\*\* (sIL-4R) and a suitable diluent or carrier.

INVENTOR(S): Namien, Anthony E.; Seattle, WA, United States  
Goodwin, Raymond G.; Seattle, WA, United States  
Laption, Stephen D.; Seattle, WA, United States  
Mochizuki, Diane Y.; Seattle, WA, United States  
PATENT ASSIGNEE(S): Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)

#### NUMBER DATE

PATENT INFORMATION: US 5714585 980203  
APPLICATION INFO.: US 94-231205 94-0421 (8)  
RELATED APPLN. INFO.: Division of Ser. No. US 92-957649 filed on 6 Oct 1992, now patented. Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-25205, filed on 7 Oct 1988, now patented. Pat. No. US 4965195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned.

#### L11 ANSWER 21 OF 52 USPATFULL

ACCESSION NUMBER: 198614755 USPATFULL  
TITLE: Antibodies that are immunoreactive with Interleukin-7

INVENTOR(S): Namien, Anthony E.; Seattle, WA, United States  
Goodwin, Raymond G.; Seattle, WA, United States  
Laption, Stephen D.; Seattle, WA, United States  
Mochizuki, Diane Y.; Seattle, WA, United States  
PATENT ASSIGNEE(S): Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)

#### NUMBER DATE

PATENT INFORMATION: US 5708157 980113  
APPLICATION INFO.: US 96-386878 960726 (8)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Walsh, Stephen  
ASSISTANT EXAMINER: Kaufman, Claire M.  
LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.;

DesRosier, Thomas J.  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Eisenchenk, Frank C.  
LEGAL REPRESENTATIVE: Davis, William J.  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1  
LINE COUNT: 3204  
CAS INDEXING IS AVAILABLE FOR THIS PATENT  
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

#### L11 ANSWER 24 OF 52 USPATFULL

ACCESSION NUMBER: 19881443 USPATFULL  
TITLE: Use of interleukin-7 to stimulate proliferation\*\*\* of hematopoietic cell precursors

INVENTOR(S): Goodwin, Raymond G.; Seattle, WA, United States  
Laption, Stephen D.; Seattle, WA, United States  
Mochizuki, Diane Y.; Seattle, WA, United States  
PATENT ASSIGNEE(S): Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)

#### NUMBER DATE

PATENT INFORMATION: US 5705149 980106  
APPLICATION INFO.: US 95-446308 950522 (8)  
RELATED APPLN. INFO.: Division of Ser. No. US 94-231205, filed on 21 Apr 1994 which is a division of Ser. No. US 92-957649, filed 6 Oct 1992, now patented. Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-25205, filed on 7 Oct 1988, now patented. Pat. No. US 4965195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned.

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Uim, John  
ASSISTANT EXAMINER: Meritz, Prema  
LEGAL REPRESENTATIVE: Davis, William J.  
NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 2052  
CAS INDEXING IS AVAILABLE FOR THIS PATENT  
AB Mammalian Interleukin-7 proteins (IL-7s), \*\*\*DNAs\*\*\* and expression vectors \*\*\*encoding\*\*\* mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

#### L11 ANSWER 25 OF 52 USPATFULL

ACCESSION NUMBER: 97-104313 USPATFULL  
TITLE: Chimeric \*\*\*receptor\*\*\* molecules for delivery of \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* signals

INVENTOR(S): Roberts, Margo R.; San Francisco, CA, United States (U.S. corporation)

#### NUMBER DATE

PATENT INFORMATION: US 5686281 971111  
APPLICATION INFO.: Call Genesys, Inc., Foster City, CA, United States (U.S. corporation)

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Uim, John  
LEGAL REPRESENTATIVE: Sughraei, Zinn, Macpeak & Seas, PLLC  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 1627  
CAS INDEXING IS AVAILABLE FOR THIS PATENT  
AB The present invention is directed to novel chimeric \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* \*\*\*receptor\*\*\* proteins and \*\*\*DNA\*\*\* sequences \*\*\*encoding\*\*\* these proteins. The chimeric \*\*\*receptors\*\*\* comprise at least three domains in a single

#### L11 ANSWER 26 OF 52 USPATFULL

ACCESSION NUMBER: 97-104313 USPATFULL  
TITLE: Chimeric \*\*\*receptor\*\*\* molecules for delivery of \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* signals

INVENTOR(S): Roberts, Margo R.; San Francisco, CA, United States (U.S. corporation)

#### NUMBER DATE

PATENT INFORMATION: US 5686281 971111  
APPLICATION INFO.: Call Genesys, Inc., Foster City, CA, United States (U.S. corporation)



**ACCESSION NUMBER:** 97:31590 USPA/TULL  
**TITLE:** Gene coded for interleukin-2 polypeptide recombinant DNA carrying the said gene, a cell line possessing the recombinant DNA, a method for producing interleukin-2 using the cell  
**INVENTOR(S):** Taniguchi, Tadatsugu, Tokyo, Japan; Muramatsu, Masami, Tokorozawa, Japan; Sugano, Haruo, Tokyo, Japan; Matsui, Hiroshi, Yokohama, Japan; Kashima, Nobukazu, Yokohama, Japan; Hanuro, Juri, Yokohama, Japan  
**PATENT ASSIGNEE(S):** Ajinomoto Co., Inc., Tokyo, Japan (corporation); Japanese Foundation for Cancer Research (Japan (non-U.S. corporation))

The present invention is directed to \*\*\*nucleic acid\*\*\* encoding \*\*\*enoding\*\*\* vespid venom phospholipases, or fragments thereof, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to expression of such nucleic acids to produce recombinant vespid venom phospholipases, or recombinant fragments derivatives or analogs thereof. Such recombinant products are useful for diagnosis of allergy and for therapeutic treatment of allergy. In specific embodiments, the present invention provides \*\*\*nucleic acid\*\*\* \*\*\*acids\*\*\* \*\*\*encoding\*\*\* and complements and amino acids sequences for, vespid venom phospholipase A<sub>1</sub>, for example, Dolichovespula maculata phospholipase A<sub>sub. 1</sub> and Vespa vulgaris phospholipase A<sub>1</sub>.

ASSISTANT EXAMINER: Spedor, Lorraine M.  
LEGAL REPRESENTATIVE: Ching, Edwin P.  
NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 288 Drawing Figure(s), 61 Drawing Page(s)  
LINE COUNT: 4619  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB **\*\*\*Nucleic acid\*\*\*** **\*\*\*acids\*\*\*** **\*\*\*encoding\*\*\*** human IL-13,  
and purified IL-13 proteins and fragments thereof. Antibodies,  
both polyclonal and monoclonal, are also provided. Methods of  
using the compositions for both diagnostic and therapeutic  
utilities are provided.

L11 ANSWER 36 OF 52 USPATFULL  
ACCESSION NUMBER: 973726 USPATFULL  
TITLE: Nucleic acid and recombinant production of vespid  
venom hyaluronidase  
INVENTOR(S): King, Te P., New York, NY, United States  
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States (U.S. corporation)

L11 ANSWER 34 OF 52 USPATFULL  
 ACCESION NUMBER: 9710123 USPATFULL  
 TITLE: Interlein-4 \*\*\*reception\*\*\*  
 INVENTOR(S): Mosley, Bruce, Seattle, WA, United States  
 Cosman, David J., Seattle, WA, United States  
 Park, Linda, Seattle, WA, United States  
 Pouschnik, M., Patricia, Poulsbo, WA, United States  
 March, Carl J., Seattle, WA, United States  
 Izquierdo, Reijan, Seattle, WA, United States  
 PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States  
 (U.S. corporation)

LINE COUNT: 2852  
CAS INDEXING: AVAILABLE FOR THIS PATENT.  
AB Mammalian Interleukin-4 \*\*\*receptor\*\*\* proteins, \*\*\*DNAs\*\*\*  
and expression vectors \*\*\*encoding\*\*\* mammalian IL-4  
\*\*\*receptors\*\*\*, and processes for producing mammalian IL-4  
\*\*\*receptors\*\*\* as products of cell culture, are disclosed. A  
method for suppressing an IL-4-dependent immune or inflammatory  
response in a mammal, including a human, by administering an  
effective amount of soluble IL-4 \*\*\*"faceptor"\*\*\* (sIL-4R) and a  
suitable diluent or carrier.

1 ANSWER 33 OF 52 USPATFULL  
ACCESSION NUMBER: 97/22653 USPATFULL  
TITLE: Cloning and recombinant production of vespid  
venom phospholipases, and immunological therapies

**PATENT ASSIGNEE(S):** Illuminex Corporation, Seattle, WA, United States  
**(U.S. corporation)**

**PATENT INFORMATION:** US 5591630 970107

**PATENT ASSIGNEE(S):** Schering Corporation, Kenilworth, NJ, United States  
Dang, Warren, San Jose, CA, United States  
Zurawski, Gerard, Redwood City, CA, United States  
McKenzie, Andrew, Redwood City, CA, United States

**DOCUMENT TYPE:** Mar 19, 1953, now abandoned  
**UTILITY**

**PRIMARY EXAMINER:** Wax, Robert A.  
**ASSISTANT EXAMINER:** Saidha, Talchand  
**LEGAL REPRESENTATIVE:** Klauber & Jackson  
**NUMBER OF CLAIMS:** 22  
**EXEMPLARIAL CLAIM:** 1  
**NUMBER OF DRAWINGS:** 7  
**LINEN COUNT:** 1852  
**CASE NUMBER:** 1852  
**CAS INDEXING IS AVAILABLE FOR THIS PATENT**

**LEGAL REPRESENTATIVE:** Perkins, Patricia Anne  
**NUMBER OF CLAIMS:** 5  
**EXEMPLARY CLAIM:** 1  
**NUMBER OF DRAWINGS:** 2 Drawing Figure(s); 2 Drawing Page(s)  
**LINE COUNT:** 1601  
**CAS INDEXING IS AVAILABLE FOR THIS PATENT.**  
**AB** There are disclosed Interleukin-15 \*\*\*Receptor\*\*\* (IL-15R) proteins, \*\*\*DNAs\*\*\* and expression vectors \*\*\*encoding\*\*\* IL-15R, and processes for producing IL-15R as products of

recombinant cell cultures. Also disclosed are monoclonal antibodies that bind interleukin-15 \*\*\*receptors\*\*\*.

L11 ANSWER 38 OF 52 USPATFULL

ACCESSION NUMBER: 9611346 USPATFULL

TITLE: B7/G fusion protein

INVENTOR(S): Lester, Jeffrey A., Seattle, WA, United States

Damle, Nitin K., Renton, WA, United States

BRADY, William, Bothell, WA, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., Seattle, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5580756 961203

APPLICATION INFO.: US 94-21518 940329 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 91-722101, filed on 27 Jun 1991 which is a continuation-in-part of Ser. No. US 90-547980, filed on 2 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 90-54849, filed on 26 Mar 1990, now abandoned

CURRENT TYPE: Utility

PRIMARY EXAMINER: Adams, Donald E.

LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Weiler & Schmidt

NUMBER OF CLAIMS: 3

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 19

Drawing Page(s); 19 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention identifies the B7 antigen as a ligand that is reactive with the CD28 \*\*\*receptor\*\*\* on T cells. Fragments and derivatives of the B7 antigen and CD28 \*\*\*receptor\*\*\* including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C gamma 1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 \*\*\*receptor\*\*\*, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 \*\*\*receptor\*\*\*, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular \*\*\*receptors\*\*\* mediating intercellular adhesion.

L11 ANSWER 39 OF 52 USPATFULL

ACCESSION NUMBER: 96106533 USPATFULL

TITLE: Antibodies to slan protein expressed on

\*\*\*activated\*\*\* T cells

INVENTOR(S): Avresa, Gregorio, Palo Alto, CA, United States

Chang, Chia-Chun I., San Jose, CA, United States

Cocks, Benjamin G., Mountain View, CA, United States

de Vries, Jan F., Los Altos, CA, United States

Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5576423 9611119

APPLICATION INFO.: US 94-348792 941202 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Nucker, Christine M.

ASSISTANT EXAMINER: Reeves, Julie E.

LEGAL REPRESENTATIVE: Ching, Edwin P.

NUMBER OF CLAIMS: 26

EXEMPLARY CLAIM: 1

LINE COUNT: 2811

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Purified \*\*\*genes\*\*\* which \*\*\*encode\*\*\* a T cell surface protein, \*\*\*specific\*\*\* antibodies, and \*\*\*nucleic\*\*\* acids\*\*\* \*\*\*encoding\*\*\* said \*\*\*antigen\*\*\*. Methods of using said reagents and diagnostic kits are also provided.

L11 ANSWER 40 OF 52 USPATFULL

ACCESSION NUMBER: 96101287 USPATFULL

TITLE: Compositions and methods for use of IL-12 as an adjuvant

INVENTOR(S): Scott, Phillip, Swarthmore, PA, United States

Trifirchian, Giorgio, Wynnewood, PA, United States

PATENT ASSIGNEE(S): The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)

The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5571515 96105

APPLICATION INFO.: US 94-265087 940617 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-229282, filed on 18 Apr 1994, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Smith, Lynette R. F.

LEGAL REPRESENTATIVE: Howson and Howson

NUMBER OF CLAIMS: 3

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13

Drawing Page(s); 7 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Improved vaccine compositions and methods of making the compositions are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of interleukin-12 (IL-12). These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.

L11 ANSWER 41 OF 52 USPATFULL

ACCESSION NUMBER: 96167750 USPATFULL

TITLE: Soluble and its use in B cell stimulation

INVENTOR(S): Autio, Alejandro, Edmonds, WA, United States

Hollenbaugh, Diane, Seattle, WA, United States

Leberbter, Jeffrey A., Seattle, WA, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Seattle, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5540926 960730

APPLICATION INFO.: US 92-540605 920904 (7)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Allen, Marianne P.

ASSISTANT EXAMINER: Spactor, L.

LEGAL REPRESENTATIVE: Penne & Edmonds

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18

Drawing Page(s); 11 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to soluble ligands for the B-cell antigen CD40, and, in particular, to human gp39 protein and soluble ligands derived therefrom which may be used in methods of promoting B-cell \*\*\*proliferation\*\*\*.

L11 ANSWER 42 OF 52 USPATFULL

ACCESSION NUMBER: 96150801 USPATFULL

TITLE: Signal transduction via CD28

INVENTOR(S): Rudd, Christopher E., Cambridge, MA, United States

Kantelli, Prasad, Boston, MA, United States

PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5525503 960611

APPLICATION INFO.: US 92-3859283 920414 (7)

DISCLAIMER DATE: 20090714

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 91-690840.

APPLICATION INFO.: US 93-128971 930928 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ziska, Suzanne E.

LEGAL REPRESENTATIVE: Fish & Richardson

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions and methods of blocking T cell signal transduction by introducing into a T cell a peptide comprising a PI 3-kinase-binding-sequence which decreases the association of PI 3-kinase with CD28. Also disclosed are compositions and methods of amplifying T cell \*\*\*activation\*\*\* by introducing into a T cell a plurality of modified T cell surface proteins, the cytoplasmic tail of which comprises a plurality of copies of a PI 3-kinase-binding-sequence.

LINE COUNT: 1056

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions and methods of blocking T cell signal transduction by introducing into a T cell a peptide comprising a PI 3-kinase-binding-sequence which decreases the association of PI 3-kinase with CD28. Also disclosed are compositions and methods of amplifying T cell \*\*\*activation\*\*\* by introducing into a T cell a plurality of modified T cell surface proteins, the cytoplasmic tail of which comprises a plurality of copies of a PI 3-kinase-binding-sequence.

NUMBER OF DRAWINGS: 1

Drawing Page(s); 7 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB

L11 ANSWER 43 OF 52 USPATFULL

ACCESSION NUMBER: 9646143 USPATFULL

TITLE: CD28/G fusion protein

INVENTOR(S): Linsley, Peter S., Seattle, WA, United States

Dame, Nitin K., Renton, WA, United States

Brady, William, Bothell, WA, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Seattle, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5521288 960328

APPLICATION INFO.: US 94-21916 940329 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 91-722101, filed on 27 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-547980, filed on 2 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 90-547980, filed on 2 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 90-49849, filed on 26 Mar 1990, now abandoned

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB

L11 ANSWER 44 OF 52 USPATFULL

ACCESSION NUMBER: 95103247 USPATFULL

TITLE: MHC class II-peptide conjugates useful in ameliorating autoimmunity

INVENTOR(S): Sharma, Somesh D., Los Altos, CA, United States

Clark, Brian R., Redwood City, CA, United States

Lerch, Bernard L., Palo Alto, CA, United States

PATENT ASSIGNEE(S): Amergen, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 568481 951121

APPLICATION INFO.: US 92-3859283 920414 (7)

DISCLAIMER DATE: 20090714

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 91-690840.

recombinant IL-2 has the principal biological activity of human IL-2; promotion of \*\*\*proliferation\*\*\* or cytotoxic \*\*\*T\*\*\* lymphocytes\*\*\*.

Filed on 23 Apr 1991, now patented. Pat. No. US 526422 which is a continuation-in-part of Ser. No. US 90-576084, filed on 30 Aug 1990, now patented. Pat. No. US 5130297 which is a continuation of Ser. No. US 88-210594, filed on 23 Jun 1988; now abandoned. A continuation-in-part of Ser. No. US 90-635840, filed on 28 Dec 1990, now patented. Pat. No. US 5284935 which is a continuation-in-part of Ser. No. US 58-367751, filed on 21 Jun 1989, now patented. Pat. No. US 5194425

DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Kim, Kay K. A.  
 ASSISTANT EXAMINER: Cunningham, T.  
 LEGAL REPRESENTATIVE: Townsend and Townsend and Crew  
 NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 35 Drawing Figure(s); 28 Drawing Page(s)  
 LINE COUNT: 2266  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

L11 ANSWER 45 OF 52 USPATFULL  
 ACCESION NUMBER: 9525014 USPATFULL  
 TITLE: Interleukin-2 polypeptides  
 INVENTOR(S): Taniguchi, Tadatsugu, Yokohama, Tokyo, United States  
 Muramatsu, Masami, Yokohama, Tokorozawa, United States  
 Sugano, Hanjo, Yokohama, Tokyo, United States  
 Matsui, Hiroshi, Yokohama, Yokohama, United States  
 Kashima, Nobukazu, Yokohama, Yokohama, United States  
 Hamuro, Junji, Yokohama, JPX, United States  
 CONFEREE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)  
 Japanese Foundation For Cancer Research, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE  
 PRIORITY INFORMATION: US 5399669 950321  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 90-531228, filed on 21 Dec 1990, now abandoned which is a continuation of Ser. No. US 89-336553, filed on 17 May 1989, now abandoned which is a continuation of Ser. No. US 87-32792, filed on 3 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-463496, filed on 3 Feb 1983, now patented. Pat. No. US 4739827

NUMBER DATE  
 PRIORITY INFORMATION: JP 82-51122 820331  
 JP 82-42509 820518  
 JP 82-219518 82215  
 JP 82-228619 821224  
 JP 82-234807 821227  
 JP 82-230371 821229  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Draper, Gamette D.  
 ASSISTANT EXAMINER: Spector, Lorraine M.  
 LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maler & Neustadt  
 NUMBER OF CLAIMS: 3  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 15 Drawing Page(s)  
 LINE COUNT: 1476  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Recombinantly produced interleukin-2 exhibits human IL-2 activity, has a molecular weight of about 15,000 daltons, is activity stable at a pH of 2-9 and is resistant to elevated temperatures. The

recombinant IL-2 has the principal biological activity of human IL-2; promotion of \*\*\*proliferation\*\*\* or cytotoxic \*\*\*T\*\*\* lymphocytes\*\*\*.

L11 ANSWER 48 OF 52 USPATFULL  
 ACCESION NUMBER: 93-93911 USPATFULL  
 TITLE: MHC conjugates useful in ameliorating autoimmune disease.

INVENTOR(S): Clark, Brian R., Redwood City, CA, United States  
 Sharma, Somesh D., Los Altos, CA, United States  
 Leach, L. Bernard, Palo Alto, CA, United States  
 PATENT ASSIGNEE(S): Aprogen, Inc., Redwood City, CA, United States  
 (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5260422 931019  
 APPLICATION INFO.: US 91-4590840 910423 (7)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 90-576084, filed on 30 Aug 1990, now patented. Pat. No. US 5130297 which is a continuation of Ser. No. US 88-210594, filed on 23 Jun 1988; now abandoned.  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Nucker, Christine M.  
 ASSISTANT EXAMINER: Cunningham, T.  
 LEGAL REPRESENTATIVE: Townsend and Townsend and Crew  
 NUMBER OF CLAIMS: 21  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 23 Drawing Page(s)  
 LINE COUNT: 1711  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptides associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

L11 ANSWER 49 OF 52 USPATFULL  
 ACCESION NUMBER: 93-14491 USPATFULL  
 TITLE: Extracellular matrix protein adherent T cells  
 INVENTOR(S): Haberman, Allan B., Somerville, MA, United States  
 PATENT ASSIGNEE(S): Trustees of Tufts College, Medford, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5188559 930223  
 APPLICATION INFO.: US 90-525512 900518 (7)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 89-414131, filed on 28 Sep 1989, now abandoned.  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Lasey, David L.  
 ASSISTANT EXAMINER: Elliott, George C.  
 LEGAL REPRESENTATIVE: Choate, Hall & Stewart  
 NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 2  
 LINE COUNT: 2225  
 AB Substantially purified mature T cells, including alpha..beta.. T cells and gamma..delta.. T cells, are capable of binding to an extracellular matrix protein, particularly to one or more of a collagen, a fibronectin, a laminin, a fibrinogen, or a proteoglycan. Also, compositions including the substantially purified ECM binding mature T cells, for use in adoptive immunotherapy in a subject. Also, methods for treating a condition in a mammal including administering to the mammal an effective quantity of the substantially purified ECM binding mature T cells, and treatment methods using the compositions. Also, methods for increasing the proportion, in a cell population, of substantially purified ECM binding mature T cells. Also, a method for assessing the likelihood that a mixture of cells contains \*\*\*activated\*\*\* T cells capable of localizing to a site in vivo, wherein an extracellular matrix protein is present at the site, in which greater binding of T cells to an extracellular matrix protein on a support in vivo indicates a greater likelihood that a mixture of cells contains \*\*\*activated\*\*\* T cells capable of localizing to the site in vivo.

L11 ANSWER 47 OF 52 USPATFULL  
 ACCESION NUMBER: 94-60237 USPATFULL  
 TITLE: Interleukin-7  
 INVENTOR(S): Namen, Anthony E., Seattle, WA, United States  
 Goodwin, Raymond G., Seattle, WA, United States  
 Lupton, Stephen D., Seattle, WA, United States  
 Mochizuki, Diane Y., Seattle, WA, United States  
 PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States  
 (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5328588 940712  
 APPLICATION INFO.: US 92-957649 921006 (7)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 89-25209, filed on 7 Oct 1989, now patented. Pat. No. US 4965195 And a continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned.  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Draper, Gamette D.  
 NUMBER OF CLAIMS: 4  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 1706  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Mammalian interleukin-7 proteins (IL-7s), \*\*\*DVAs\*\*\* and expression vectors \*\*\*encoding\*\*\* mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L11 ANSWER 50 OF 52 USPATFULL  
 ACCESION NUMBER: 91-40676 USPATFULL  
 TITLE: Mammalian interleukin-4

INVENTOR(S): Lee, Frank; Palo Alto, CA, United States  
Yokota, Takashi; Palo Alto, CA, United States  
Arai, Ken-Ichi; Palo Alto, CA, United States  
Mosmann, Timothy; Alhambra, CA, United States  
RENNICK, Donna; Los Altos, CA, United States

PATENT ASSIGNEE(S): Schering Corporation, Madison, NJ, United States  
(U.S. corporation)

Patent Assignee(s): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

Patent Assignee(s): US 83-463496 83/0203 (6)

NUMBER DATE

PATENT INFORMATION: US 5017691 9/10/52  
DISCLAIMER INFO.: US 86-808215 86/09/17 (6)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 86-881553,  
filed on 3 Jul 1986; now abandoned which is a  
continuation-in-part of Ser. No. US 85-843958,  
filed on 25 Mar 1986 which is a  
continuation-in-part of Ser. No. US 85-794688,  
filed on 19 Nov 1985; now abandoned

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Taskin, Robin  
ASSISTANT EXAMINER: Ellis, Joan  
LEGAL REPRESENTATIVE: Macavitz, Stephen C.

EXEMPLARY CLAIM: 9

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 2748

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian proteins and mutants thereof, designated interleukin-4s

(IL-4s), are provided which exhibit both B cell "growth"\*\*\*

factor activity and T cell "growth"\*\*\* factor activity.

Compounds of the invention include native human and murine IL-4s, mutants thereof, and nucleic acids which are effectively homologous to disclosed cDNAs and/or which are capable of coding for mammalian IL-4s and their mutants.

L11 ANSWER 51 OF 52 USPAFULL

ACCESSION NUMBER: 90-81722 USPAFULL

TITLE: Interleukin-7

INVENTOR(S): Namen, Anthony E.; Seattle, WA, United States  
Goodwin, Raymond G.; Seattle, WA, United States  
Lupton, Stephen D.; Seattle, WA, United States  
Mochizuki, Dianne Y.; Seattle, WA, United States

PATENT ASSIGNEE(S): Immunex Corp., Seattle, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4985196 9/01/23

APPLICATION INFO.: US 88-252209 88/007 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 87-113666,

filed on 26 Oct 1987

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Wissman, Thomas G.

ASSISTANT EXAMINER: Ellis, Joan

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian interleukin-7 proteins (IL-7s), \*\*\*DNAs\*\*\* and expression vectors \*\*\*encoding\*\*\* mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L11 ANSWER 52 OF 52 USPAFULL

ACCESSION NUMBER: 88-24371 USPAFULL

TITLE: Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan  
Muramatsu, Masami, Tokorozawa, Japan  
 Sugano, Hano, Tokyo, Japan  
 Matsui, Hiroshi, Yokohama, Japan  
Kashima, Nobukazu, Yokohama, Japan

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

Patent Assignee(s): US 83-463496 83/0203 (6)

NUMBER DATE

PATENT INFORMATION: JP 52-51122 82/0331  
PRIORITY INFORMATION: JP 82-82505 82/0318  
JP 82-82518 82/1215  
JP 82-219518 82/1224  
JP 82-234607 82/1227  
JP 82-230371 82/1228

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Marinelli, James

LEGAL REPRESENTATIVE: Obion, Fisher, Spivak, McClelland & Maier

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Figure(s); 9 Drawing Page(s)

LINE COUNT: 1478

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A gene coded for a polypeptide which possesses interleukin-2 activity is isolated, and connected with a vector DNA which is capable of replicating in a prokaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.

=> s (I2 and I6) and ((nucleic)acid or dna or cda or gene or polynucleotide)(4)encod?

L12 4465 (L2 AND L6) AND ((NUCLEIC)(W) ACID OR DNA OR CDNA OR GENE OR POLYNUCLEOTIDE)(KA) ENCOD?)

=> dup rem

ENTER L# LIST OR (END):12

L13 2656 DUP REM L12 (1809 DUPLICATES REMOVED)

=> s l13 and extracell?

L14 666 L13 AND EXTRACELL?

=> dup rem

L15 53 L0 AND EXTRACELL?

=> dup rem

ENTER L# LIST OR (END):15

PROCESSING COMPLETED FOR L15

L16 46 DUP REM L15 (7 DUPLICATES REMOVED)

=> s l11 and extracell?

L17 41 L11 AND EXTRACELL?

=> s l11 and (intracell? or cytoplasm?)

L18 48 L11 AND (INTRACELL? OR CYTOPLASM?)

=> s l11 and label?

L19 44 L11 AND LABEL?

=> s l11 and kit

L20 26 L11 AND KIT

=> d l20 1-26 ibib ab

NUMBER DATE

PATENT INFORMATION: US 5792628 98/0811

APPLICATION INFO.: US 97-418163 97/0314 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Grimes, Eric

ASSISTANT EXAMINER: Longton, Enrique D.

LEGAL REPRESENTATIVE: Brown, Scott A.

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

LINE COUNT: 1440

AB A novel secreted protein, BA3.1, is disclosed. Polynucleotides encoding BA3.1 are also provided.

NUMBER DATE

PATENT INFORMATION: US 5792628 98/0811

APPLICATION INFO.: US 97-418163 97/0314 (8)

DOCUMENT TYPE: Secreted proteins and polynucleotides encoding them

INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States

McCoy, John M., Reading, MA, United States

LaValle, Edward R., Tewksbury, MA, United States

Racie, Lisa A., Acton, MA, United States

Menberg, David, Acton, MA, United States

Tracey, Maurice, Chestnut Hill, MA, United States

Saulsbury, Vicki, Billerica, MA, United States

Genetics Institute, Inc., Cambridge, MA, United States

States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5788465 98/0728

APPLICATION INFO.: US 96-721489 96/0927 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 96-688878, filed on 26 Jul 1996

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kaufman, Claire M.

ASSISTANT EXAMINER: Waisl, Stephen

LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20

LINE COUNT: 1564

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel polynucleotides and the proteins encoded thereby are disclosed.

NUMBER DATE

PATENT INFORMATION: US 5788465 98/0728

APPLICATION INFO.: US 96-721489 96/0927 (8)

DOCUMENT TYPE: Method to identify compounds which modulate ICAM-related protein interactions

INVENTOR(S): Gallatin, V. Michael, Seattle, WA, United States

Vazeer, Rosemary, Seattle, WA, United States

ICOS Corporation, Bothell, WA, United States

PATENT ASSIGNEE(S): (U.S. corporation)

Patent Assignee(s): US 92-889724 filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 27 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now

<b>DOCUMENT TYPE:</b> Utility <b>PRIMARY EXAMINER:</b> Allen, Marianne P. <b>ASSISTANT EXAMINER:</b> Brown, Karen E. <b>LEGAL REPRESENTATIVE:</b> Marshall, O'Tools, Gerstein, Murray & Bonin <b>NUMBER OF CLAIMS:</b> 2 <b>EXEMPLARY CLAIM:</b> 1 <b>NUMBER OF DRAWINGS:</b> 39 Drawing Figure(s); 34 Drawing Page(s) <b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b> <b>AB</b> ***DNA*** sequences ***encoding*** a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.	<b>RELATED APPLN. INFO.:</b> Continuation-in-part of Ser. No. US 93-13621, filed on 13 Oct 1993, now abandoned <b>DOCUMENT TYPE:</b> Utility <b>PRIMARY EXAMINER:</b> Caputa, Anthony C. <b>LEGAL REPRESENTATIVE:</b> Townsend and Townsend and Crew LLP <b>NUMBER OF CLAIMS:</b> 11 <b>EXEMPLARY CLAIM:</b> 1 <b>NUMBER OF DRAWINGS:</b> 14 Drawing Figure(s); 8 Drawing Page(s) <b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b> <b>AB</b> The present invention provides a method for the purification and characterization of MHC-peptide complexes useful in ameliorating immunological disorders, such as, for example, autoimmune diseases, allergic responses and transplant rejection. The method disclosed is a one-step method based on the use of metal chelate affinity chromatography to separate the MHC-peptide complexes of interest from both uncomplexed MHC molecules and other endogenous MHC-peptide bound complexes.
<b>L20 ANSWER 6 OF 26 USPATFULL</b> <b>ACCESSION NUMBER:</b> 1998-561171 USPATFULL <b>TITLE:</b> Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines <b>INVENTOR(S):</b> Ladd, Anna Elm Brooklyn, NY, United States <b>PATENT ASSIGNEE(S):</b> Wang, Chang Yi, Cold Spring Harbor, NY, United States <b>ZAMB:</b> Timothy Joseph, Stony Brook, NY, United States <b>PATENT ASSIGNEE(S):</b> United Biomedical Inc., Hauppauge, NY, United States (U.S. corporation)	<b>L20 ANSWER 6 OF 26 USPATFULL</b> <b>ACCESSION NUMBER:</b> 1998-561171 USPATFULL <b>TITLE:</b> Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines <b>INVENTOR(S):</b> Ladd, Anna Elm Brooklyn, NY, United States <b>PATENT ASSIGNEE(S):</b> Wang, Chang Yi, Cold Spring Harbor, NY, United States <b>ZAMB:</b> Timothy Joseph, Stony Brook, NY, United States <b>PATENT ASSIGNEE(S):</b> United Biomedical Inc., Hauppauge, NY, United States (U.S. corporation)
<b>L20 ANSWER 4 OF 26 USPATFULL</b> <b>ACCESSION NUMBER:</b> 1998-572709 USPATFULL <b>TITLE:</b> ICAM-related protein fragments <b>INVENTOR(S):</b> Gallatin, W Michael Seattle, WA, United States <b>PATENT ASSIGNEE(S):</b> Vazeaux, Rosemarie Seattle, WA, United States <b>PATENT INFORMATION:</b> US 57770666 980623 <b>APPLICATION INFO.:</b> US 95-474368 950507 (8) filed on 20 Apr 1995, now abandoned which is a continuation of Ser. No. US 95-425870 filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-32260, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-894051, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part or Ser. No. US 92-8271693, filed on 27 Jan 1992, now abandoned	<b>PATENT INFORMATION:</b> US 5759551 980602 <b>APPLICATION INFO.:</b> US 94-25050 941110 <b>PCT INFORMATION:</b> WO 94-446592 951226 (8) <b>PCT INFORMATION:</b> WO 94-446592 951226 (8) <b>PCT INFORMATION:</b> WO 94-446592 951226 (8) <b>PCT INFORMATION:</b> 951226 PCT 102(e) date <b>PATENT INFORMATION:</b> US 95-488351, filed on 7 Jul 1995 <b>DOCUMENT TYPE:</b> Utility <b>PRIMARY EXAMINER:</b> Smith, Lynette F.

NUMBER	DATE
PATENT INFORMATION:	US 5747034 980505
APPLICATION INFO.:	US 94-200716 340218 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-15147, filed on 9 Feb 1993 which is a continuation-in-part of Ser. No. US 92-910222, filed on 9 Jul 1992, now patented. Pat. No. US 5397703
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Loring, Susan A.
LEGAL REPRESENTATIVE:	Pochopien, Donald J.; Saveirede, Paul B.; Blackburn, Robert P.
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT:	2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce ***antigen*** - ***specific*** tolerance.
The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.	
L20 ANSWER 8 OF 26 USPATFULL	
ACCESSION NUMBER:	1998:28196 USPATFULL
TITLE:	Secreted proteins and polynucleotides encoding them
INVENTOR(S):	Jacobs, Kenneth, Newton, MA, United States McCoy, John M., Reading, MA, United States LaValle, Edward R., Tewksbury, MA, United States Racie, Lisa A., Acton, MA, United States Marberg, David, Acton, MA, United States Tracey, Maurice, Chestnut Hill, MA, United States Evans, Cheryl, Brookline, MA, United States Spaulding, Vicki, Billerica, MA, United States PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)
NUMBER	DATE
PATENT INFORMATION:	US 5728819 980317
APPLICATION INFO.:	US 96-691641 980802 (8)
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Walsh, Stephen M.
ASSISTANT EXAMINER:	Kaufman, Claire M.
LEGAL REPRESENTATIVE:	Brown, Scott A.; DesRosier, Thomas J.
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1
LINE COUNT:	1864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	Novel polynucleotides and the proteins encoded thereby are disclosed.
L20 ANSWER 9 OF 26 USPATFULL	
ACCESSION NUMBER:	1998:22079 USPATFULL
TITLE:	Secreted proteins and polynucleotides encoding them
INVENTOR(S):	Jacobs, Kenneth, Newton, MA, United States McCoy, John M., Reading, MA, United States LaValle, Edward R., Tewksbury, MA, United States Racie, Lisa A., Acton, MA, United States Marberg, David, Acton, MA, United States Tracey, Maurice, Chestnut Hill, MA, United States Spaulding, Vicki, Billerica, MA, United States PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)
NUMBER	DATE

PATENT INFORMATION: US 5723315 980303  
APPLICATION INFO.: US 96-07344 9608023 (8)  
DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Walsh, Stephen  
ASSISTANT EXAMINER: Kaufman, Claire M.  
LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.;  
DasRosier, Thomas J.

NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2437  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel polypeptides and the proteins encoded thereby are disclosed.

L20 ANSWER 10 OF 26 USPATFULL  
ACCESSION NUMBER: 1998-17059 USPATFULL  
TITLE: Transgenic animal for autoimmune diseases

INVENTOR(S): Harten, David M.; Pajomac, MD, United States  
June, Can H., Rockville, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)

NUMBER DATE  
INVENTOR(S): Campbell, Bruce R.  
LEGAL REPRESENTATIVE: Spavack, A.; David; Mandragouras, Amy E.; Lahive & Cockfield, LLP

NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 11 Drawing Page(s)

DOCUMENT TYPE: Utility  
filed on 14 Apr 1993, now abandoned

PRIMARY EXAMINER: Campbell, Bruce R.  
LEGAL REPRESENTATIVE: Spavack, A.; David; Mandragouras, Amy E.; Lahive & Cockfield, LLP

NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 141

INVENTOR(S): A transgenic animal, whose germ cells and somatic cells contain a transgene including a \*\*\*DNA\*\*\* sequence \*\*\*encoding\*\*\* a CD28 ligand and a tissue-specific promoter operably linked to the DNA sequence, wherein the tissue-specific promoter effects expression of the CD28 ligand in cells of a specific tissue of the animal. This animal serves as a transgenic model for specific autoimmune diseases.

L20 ANSWER 11 OF 26 USPATFULL  
ACCESSION NUMBER: 1998-12125 USPATFULL  
TITLE: Antibodies that are immunoreactive with interleukin-7

INVENTOR(S): Namen, Anthony E., Seattle, WA, United States  
Goodwin, Raymond G., Seattle, WA, United States  
Lupton, Stephen D., Seattle, WA, United States  
Mochizuki, Diane Y., Seattle, WA, United States  
PATENT ASSIGNEE(S): Sterling Winthrop, Inc., New York, NY, United States (U.S. corporation)

NUMBER DATE  
INVENTOR(S): US 94-231205 940421 (8)

APPLICATION INFO.: Division of Ser. No. US 92-957649, filed on 6 Oct 1992, now abandoned. Pat. No. US 5328988 which is a continuation or Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned. Pat. No. US 4965195 which is a continuation-in-part of Ser. No. US 88-252209, filed on 7 Oct 1988, now abandoned. Pat. No. US 4865195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned.

DOCUMENT TYPE:  
PRIMARY EXAMINER: Eisenschank, Frank C.  
LEGAL REPRESENTATIVE: Davis, William J.  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1963  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel polynucleotides and the proteins encoded thereby are

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibodies that are immunoreactive with interleukin-7 (IL-7) proteins are provided. The anti-IL-7 antibodies may be polyclonal or monoclonal. Certain embodiments are directed to antibodies that are immunoreactive with human IL-7.

LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.;

DosRosier, Thomas J.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 2437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel polypeptides and the proteins encoded thereby are disclosed.

L20 ANSWER 10 OF 26 USPATFULL  
ACCESSION NUMBER: 1998-17059 USPATFULL  
TITLE: Transgenic animal for autoimmune diseases

INVENTOR(S): Harten, David M.; Pajomac, MD, United States  
June, Can H., Rockville, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)

NUMBER DATE  
INVENTOR(S): Campbell, Bruce R.  
LEGAL REPRESENTATIVE: Spavack, A.; David; Mandragouras, Amy E.; Lahive & Cockfield, LLP

NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 11 Drawing Page(s)

DOCUMENT TYPE: Utility  
filed on 14 Apr 1993, now abandoned

PRIMARY EXAMINER: Campbell, Bruce R.  
LEGAL REPRESENTATIVE: Spavack, A.; David; Mandragouras, Amy E.; Lahive & Cockfield, LLP

NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 141

INVENTOR(S): A transgenic animal, whose germ cells and somatic cells contain a transgene including a \*\*\*DNA\*\*\* sequence \*\*\*encoding\*\*\* a CD28 ligand and a tissue-specific promoter operably linked to the DNA sequence, wherein the tissue-specific promoter effects expression of the CD28 ligand in cells of a specific tissue of the animal. This animal serves as a transgenic model for specific autoimmune diseases.

L20 ANSWER 11 OF 26 USPATFULL  
ACCESSION NUMBER: 1998-12125 USPATFULL  
TITLE: Antibodies that are immunoreactive with interleukin-7

INVENTOR(S): Namen, Anthony E., Seattle, WA, United States  
Goodwin, Raymond G., Seattle, WA, United States  
Lupton, Stephen D., Seattle, WA, United States  
Mochizuki, Diane Y., Seattle, WA, United States  
PATENT ASSIGNEE(S): Sterling Winthrop, Inc., New York, NY, United States (U.S. corporation)

NUMBER DATE  
INVENTOR(S): US 94-231205 940421 (8)

APPLICATION INFO.: Division of Ser. No. US 92-957649, filed on 6 Oct 1992, now abandoned. Pat. No. US 5328988 which is a continuation or Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned. Pat. No. US 4965195 which is a continuation-in-part of Ser. No. US 88-252209, filed on 7 Oct 1988, now abandoned. Pat. No. US 4865195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned.

DOCUMENT TYPE:  
PRIMARY EXAMINER: Eisenschank, Frank C.  
LEGAL REPRESENTATIVE: Davis, William J.  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1963  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel polynucleotides and the proteins encoded thereby are

disclosed.

L20 ANSWER 14 OF 26 USPATFULL  
ACCESSION NUMBER: 1998-1443 USPATFULL  
TITLE: Use of interleukin-7 to stimulate proliferation \*\*\* of hematopoietic cell precursors

INVENTOR(S): Namen, Anthony E., Seattle, WA, United States  
Goodwin, Raymond G., Seattle, WA, United States  
Lupton, Stephen D., Seattle, WA, United States  
Mochizuki, Diane Y., Seattle, WA, United States  
PATENT ASSIGNEE(S): Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5705149 980106  
APPLICATION INFO.: US 55-446508 850522 (8)  
RELATED APPLN. INFO.: Division of Ser. No. US 94-231205, filed on 21 Apr 1994, which is a division of Ser. No. US 92-957649, filed on 6 Oct 1992, now patented, Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-252209, filed on 7 Oct 1988, now patented, Pat. No. US 4965195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned.

DOCUMENT TYPE:  
PRIMARY EXAMINER: Ulm, John  
ASSISTANT EXAMINER: Mertz, Prerna  
LEGAL REPRESENTATIVE: Davis, William J.  
NUMBER OF CLAIMS: 10  
NUMBER OF DRAWINGS: 1  
EXEMPLAR CLAIM: 1  
LINE COUNT: 2052  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-7 proteins (IL-7s), \*\*\*DNAs\*\*\* and expression vectors \*\*\*encoding\*\*\* mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L20 ANSWER 15 OF 26 USPATFULL  
ACCESSION NUMBER: 97-104313 USPATFULL  
TITLE: Chimeric \*\*\*receptor\*\*\* molecules for delivery of \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* signals

INVENTOR(S): Roberts, Margo R., San Francisco, CA, United States (U.S. corporation)

NUMBER DATE  
INVENTOR(S): Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)

PATENT INFORMATION: US 5686281 971111  
APPLICATION INFO.: US 95-45580 950531 (8)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 95-383749, filed on 3 Feb 1995

DOCUMENT TYPE:  
PRIMARY EXAMINER: Ulm, John  
LEGAL REPRESENTATIVE: Sugihara,Mion,Zinn,Macpeak & Seas, PLLC  
NUMBER OF CLAIMS: 11  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention is directed to novel chimeric \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* effector function signaling domain that acts synergistically with an effector function signal in the host cell. Novel hybrid \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* proteins. The chimeric \*\*\*receptors\*\*\* comprise at least three domains in a single chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* effector function signaling domain that acts synergistically with an effector function signal in the host cell. proteins include a second cytoplasmic effector function signaling domain. The invention further relates to expression cassettes

L20 ANSWER 12 OF 26 USPATFULL  
ACCESSION NUMBER: 1998-9379 USPATFULL  
TITLE: Chimeric \*\*\*receptor\*\*\* molecules for delivery of \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* signals

INVENTOR(S): Roberts, Margo R., San Francisco, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5712149 980127  
APPLICATION INFO.: US 95-383749 950203 (8)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Ulm, John  
LEGAL REPRESENTATIVE: Sugihara,Mion,Zinn,Macpeak & Seas, PLLC  
NUMBER OF CLAIMS: 25  
EXEMPLAR CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)

DOCUMENT TYPE:  
PRIMARY EXAMINER: Ulm, John  
ASSISTANT EXAMINER: Mertz, Prerna  
LEGAL REPRESENTATIVE: Davis, William J.  
NUMBER OF CLAIMS: 10  
NUMBER OF DRAWINGS: 1  
EXEMPLAR CLAIM: 1  
LINE COUNT: 2052  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-7 proteins (IL-7s), \*\*\*DNAs\*\*\* and expression vectors \*\*\*encoding\*\*\* mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L20 ANSWER 15 OF 26 USPATFULL  
ACCESSION NUMBER: 97-104313 USPATFULL  
TITLE: Chimeric \*\*\*receptor\*\*\* molecules for delivery of \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* signals

INVENTOR(S): Roberts, Margo R., San Francisco, CA, United States (U.S. corporation)

NUMBER DATE  
INVENTOR(S): Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)

PATENT INFORMATION: US 5686281 971111  
APPLICATION INFO.: US 95-45580 950531 (8)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 95-383749, filed on 3 Feb 1995

DOCUMENT TYPE:  
PRIMARY EXAMINER: Ulm, John  
LEGAL REPRESENTATIVE: Sugihara,Mion,Zinn,Macpeak & Seas, PLLC  
NUMBER OF CLAIMS: 11  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention is directed to novel chimeric \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* effector function signaling domain that acts synergistically with an effector function signal in the host cell. Novel hybrid \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* proteins. The chimeric \*\*\*receptors\*\*\* comprise at least three domains in a single chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic \*\*\*co\*\*\* - \*\*\*stimulatory\*\*\* effector function signaling domain that acts synergistically with an effector function signal in the host cell. proteins include a second cytoplasmic effector function signaling domain. The invention further relates to expression cassettes

containing the \*\*\*nucleic\*\*\* \*\*\*acids\*\*\* \*\*\*"encoding"\*\*\* the novel chimeric \*\*\*receptors\*\*\*, to host cells expressing the novel chimeric \*\*\*receptors\*\*\* and to methods of using the \*\*\*receptors\*\*\* to \*\*\*co\*\*\*-\*\*\*stimulate\*\*\* effector functions in the cells and for using cells expressing the \*\*\*receptors\*\*\* for treatment of cancer, disease and viral infections.

L20 ANSWER 16 OF 26 USPATFULL  
APPLICATION NUMBER: 9778562 USPATFULL  
TITLE: ICAM-related protein  
INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States  
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5648219 970715  
APPLICATION INFO.: US 95-479882 950607 (8)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Chan, Christina Y.  
ASSISTANT EXAMINER: Vanderlegt, E. Pierre  
LEGAL REPRESENTATIVE: Sawislak, Deborah A.; Parker, Gary E.; Leith, Debra K.

NUMBER OF CLAIMS: 15  
NUMBER OF DRAWINGS: 4  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
LINE COUNT: 1020  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides an immature dendritic cell line derived from p53 \*\*\*growth\*\*\* suppressor gene deficient animals. The immature dendritic cell line may be induced to become an \*\*\*activated\*\*\* dendritic cell line that will stimulate T-cells to \*\*\*proliferate\*\*\*. The cell line is useful for presentation of antigens involved in autoimmune disease and analysis of peptides that produce a T-cell response.

L20 ANSWER 17 OF 26 USPATFULL  
APPLICATION NUMBER: 95-433010 950603 (8)  
TITLE: Cloning and recombinant production of vespid venom phospholipases, and immunological therapies based thereon  
INVENTOR(S): King, Te P., New York, NY, United States  
PATENT ASSIGNEE(S): "The Rockefeller University, New York, NY, United States (U.S. corporation)"  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Ullm, John  
ASSISTANT EXAMINER: Brown, Karen E.  
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Bonan  
NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 16  
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 23 Drawing Page(s)  
LINE COUNT: 2834  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB \*\*\*DNA\*\*\* sequences, \*\*\*"encoding"\*\*\* a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/ \*\*\*"receptor"\*\*\* binding biological activities of ICAM-R.

L20 ANSWER 17 OF 26 USPATFULL  
ACCESSION NUMBER: 97-68346 USPATFULL  
TITLE: Secreted proteins and polypeptides encoding them  
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States  
McCoy, John M., Reading, MA, United States  
Lavalley, Edward R., Tewksbury, MA, United States  
Racine, Lisa A., Acton, MA, United States  
Mertberg, David, Acton, MA, United States  
Tracy, Maurice, Chestnut Hill, MA, United States  
Spaulding, Vicki, Billerica, MA, United States  
Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5654173 970805  
APPLICATION INFO.: US 96-702080 960823 (8)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Jagannathan, Vasu S.  
ASSISTANT EXAMINER: Jephcott, Brian  
LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1685  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel polypeptides and the proteins encoded thereby are disclosed.

L20 ANSWER 18 OF 26 USPATFULL  
ACCESSION NUMBER: 97-61556 USPATFULL  
TITLE: Method of refolding human IL-13  
INVENTOR(S): Cuiperpeper, Janice, Mountain View, CA, United States  
McKenzie, Andrew, Redwood City, CA, United States  
Dang, Warren, San Jose, CA, United States  
Zurawski, Gerard, Redwood City, CA, United States  
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5576423 961119  
APPLICATION INFO.: US 94-348792 941202 (8)  
DOCUMENT TYPE: Utility

TITLE: Immortalized dendritic cells  
INVENTOR(S): MacKay, Vivian L., Seattle, WA, United States  
Moore, Emma E., Seattle, WA, United States  
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5586072 970124  
APPLICATION INFO.: US 93-12543 860201 (8)  
RELATED APPLN INFO.: Continuation-in-part of Ser. No. US 92-933416, filed on 21 Aug 1992, now abandoned  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Draper, Gamette D.  
ASSISTANT EXAMINER: Spader, Lorraine M.  
LEGAL REPRESENTATIVE: Ching, Edwin P.  
NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 288 Drawing Figure(s); 61 Drawing Page(s)  
LINE COUNT: 4619  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB \*\*\*"Nucleic"\*\*\* \*\*\*"acids"\*\*\* \*\*\*"encoding"\*\*\* human IL-13, and purified IL-13 proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

L20 ANSWER 21 OF 26 USPATFULL  
ACCESSION NUMBER: 97-3726 USPATFULL  
TITLE: Nucleic acid and recombinant production of vespid venom hyaluronidase  
INVENTOR(S): King, Te P., New York, NY, United States  
PATENT ASSIGNEE(S): "The Rockefeller University, New York, NY, United States (U.S. corporation)"  
DOCUMENT TYPE: Utility  
NUMBER DATE  
PRIMARY EXAMINER: Walsh, Stephen G.  
LEGAL REPRESENTATIVE: Klauber & Jackson  
NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)  
LINE COUNT: 2479  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention is directed to \*\*\*"nucleic"\*\*\* \*\*\*"acids"\*\*\* \*\*\*"encoding"\*\*\* vespid venom enzymes, or fragments thereof, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to expression of such nucleic acids to produce recombinant vespid venom enzymes, or recombinant fragments, derivatives or analogs thereof. Such recombinant products are useful for diagnosis of allergy and for therapeutic treatment of allergy. In specific embodiments, the present invention provides \*\*\*"nucleic"\*\*\* \*\*\*"acids"\*\*\* \*\*\*"encoding"\*\*\*, and complete nucleotide and amino acid sequences for, vespid venom phospholipase, for example, Dolichovespula maculata phospholipase and Vespa vulgaris phospholipase, and vespid venom hyaluronidase, for example, Dolichovespula maculata hyaluronidase.

L20 ANSWER 22 OF 26 USPATFULL  
ACCESSION NUMBER: 96-106533 USPATFULL  
TITLE: Antibodies to the slam protein expressed on T cells  
INVENTOR(S): Aversa, Gregorio, Palo Alto, CA, United States  
Chang, Chia-Chun J., San Jose, CA, United States  
Cocks, Benjamin G., Mountain View, CA, United States  
de Vries, Jan E., Los Altos, CA, United States  
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5576423 961119  
APPLICATION INFO.: US 94-348792 941202 (8)  
DOCUMENT TYPE: Utility

**PRIMARY EXAMINER:** Nucker, Christine M.  
**ASSISTANT EXAMINER:** Reeves, Julie E.  
**LEGAL REPRESENTATIVE:** Ching, Edwin P.  
**NUMBER OF CLAIMS:** 26  
**EXNLINE COUNT:** 1  
**CAS INDEXING IS AVAILABLE FOR THIS PATENT.**

**AB** Purified \*\*\*genes\*\*\* which \*\*\*encode\*\*\* a T cell surface antigen from a mammal, reagents related thereto including purified proteins, \*\*\*specific\*\*\* antibodies, and \*\*\*therapeutic\*\*\* acids\*\*\* \*\*\*encoding\*\*\* said \*\*\*antigen\*\*\*. Methods of using said reagents and diagnostic \*\*\*kits\*\*\* are also provided.

L20 ANSWER 23 OF 26 USPATFULL  
 ACCESION NUMBER: 96-56801 USPATFULL  
 TITLE: Signal transduction via CD28  
 INVENTOR(S): Rudd, Christopher E., Cambridge, MA, United States  
 Status: Katriel, Prasad, Boston, MA, United States  
 PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

NUMBER	DATE
1	PATENT INFORMATION: US 5525503 960611 APPLICATION INFO.: US 93-128971 930928 (8) DOCUMENT TYPE: Utility PRIMARY EXAMINER: Ziskar, Suzanne E. LEGAL REPRESENTATIVE: Fish & Richardson NUMBER OF CLAIMS: 2 EXEMPLARY DRAWINGS: 1 NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s) LINE COUNT: 1056 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB Disclosed are compositions and methods of blocking T cell signal transduction by introducing into a T cell a peptide comprising a PI 3-kinase-binding sequence which decreases the association of PI 3-kinase with CD28. Also disclosed are compositions and methods of amplifying T cell ***activation*** by introducing into a T cell a plurality of modified T cell surface proteins, the cytoplasmic tail of which comprises a plurality of copies of a PI 3-kinase-binding sequence.

L20 ANSWER 24 OF 26 USPATFULL  
 ACCESION NUMBER: 95-103247 USPATFULL  
 TITLE: MHC class II-peptide conjugates useful in ameliorating autoimmune disease  
 INVENTOR(S): Shamma, Somesh D., Los Altos, CA, United States  
 Clark, Brian R., Palo Alto, CA, United States  
 Larch, Bernard L., Palo Alto, CA, United States  
 PATENT ASSIGNEE(S): Amrogen, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER	DATE
1	PATENT INFORMATION: US 5468481 951121 APPLICATION INFO.: US 92-869293 920414 (7) DISCLAIMER DATE: 20060114 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 91-690840, filed on 23 Apr 1991, now patented. Pat. No. US 5260422 which is a continuation-in-part of Ser. No. US 90-575084, filed on 30 Aug 1990, now patented. Pat. No. US 5130297 which is a continuation of Ser. No. US 88-210594, filed on 23 Jun 1988, now abandoned. And a continuation-in-part of Ser. No. US 90-635840, filed on 28 Dec 1990, now patented. Pat. No. US 5284935 which is a continuation-in-part of Ser. No. US 85-367751, filed on 21 Jun 1989, now patented. Pat. No. US 5194425 DOCUMENT TYPE: Primary Examiner: Kim, Kay K. A. Assistant Examiner: Cunningham, T. Legal Representative: Townsend and Townsend and Crew NUMBER OF CLAIMS: 22 EXEMPLARY CLAIM: 1

**NUMBER OF DRAWINGS:** 35 Drawing Figure(s); 26 Drawing Page(s)  
**LINE COUNT:** 2266  
**CAS INDEXING IS AVAILABLE FOR THIS PATENT.**  
**AB** The present invention is directed to complexes consisting essentially of an isolated MHC component and an autointeracting peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

L20 ANSWER 25 OF 26 USPATFULL  
 ACCESION NUMBER: 94-60237 USPATFULL  
 TITLE: Interleukin-7  
 INVENTOR(S): Namen, Anthony E., Seattle, WA, United States  
 Goodwin, Raymond G., Seattle, WA, United States  
 Lupton, Stephen D., Seattle, WA, United States  
 Mochizuki, Diane Y., Seattle, WA, United States  
 PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	DATE
1	PATENT INFORMATION: US 5329898 940712 APPLICATION INFO.: US 92-357649 921006 (7) RELATED APPLN. INFO.: Continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 89-25208, filed on 10 Oct 1989, now patented. Pat. No. US 4965195 And a continuation-in-part of Ser. No. US 87-113566, filed on 28 Oct 1987, now abandoned DOCUMENT TYPE: Utility PRIMARY EXAMINER: Draper, Gamette D. NUMBER OF CLAIMS: 4 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s) LINE COUNT: 1706 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB Mammalian Interleukin-7 proteins (IL-7s), ***DNAs*** and expression vectors ***encoding*** mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L20 ANSWER 26 OF 26 USPATFULL  
 ACCESION NUMBER: 90-81722 USPATFULL  
 TITLE: Interleukin-7  
 INVENTOR(S): Namen, Anthony E., Seattle, WA, United States  
 Goodwin, Raymond G., Seattle, WA, United States  
 Lupton, Stephen D., Seattle, WA, United States  
 Mochizuki, Diane Y., Seattle, WA, United States  
 PATENT ASSIGNEE(S): Immunex Corp., Seattle, WA, United States (U.S. corporation)

NUMBER	DATE
1	PATENT INFORMATION: US 4965195 901023 APPLICATION INFO.: US 88-25209 881007 (7) RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987 DOCUMENT TYPE: Utility PRIMARY EXAMINER: Wiseman, Thomas G. ASSISTANT EXAMINER: Wiesman, Joan NUMBER OF CLAIMS: 17 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s) LINE COUNT: 1714 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB Mammalian Interleukin-7 proteins (IL-7s), ***DNAs*** and expression vectors ***encoding*** mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

>> s 113 and kit

L21 637 L13 AND KIT  
 => s 121 and kit

L22 637 L21 AND KIT

=> s 121 and extracellular?

L23 313 L21 AND EXTRACELL?  
 => s 113 and vector

L24 92 L13 AND VECTOR  
 => dup rem

ENTER L# LIST OR (END)124  
 PROCESSING COMPLETED FOR L24  
 L25 88 DUP REM L24 (4 DUPLICATES REMOVED)  
 => d 125 1-88 itsb ab

L25 ANSWER 1 OF 88 USPATFULL  
 ACCESION NUMBER: 1998-15817 USPATFULL  
 TITLE: Cathepsin and methods and compositions for inhibition thereof  
 INVENTOR(S): Tung, Jay S., 2224 Samaria Ave., Belmont, CA,  
 United States 94002  
 Shinia, Sukanto, 808 Junipero Serra Blvd., San Francisco, CA, United States 94127  
 McConlogue, Lisa, 283 Juanita Way, San Francisco, CA, United States 94127  
 Tatsumi, Gwen, 5910 Pinewood Rd., Oakland, CA, United States 94631  
 Anderson, John, 21 Bucareli Dr., San Francisco, CA, United States 94132  
 Chrysler, Susanna, 448-112 San Bruno Ave., Brisbane, CA, United States 94005  
 NUMBER DATE  
 NUMBER OF CLAIMS: 2  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 9 Drawing Figure(s); 10 Drawing Page(s)  
 LINE COUNT: 2303  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
**AB** Methods for inhibiting the secretion of beta-amyloid peptide (beta-AP) from cells comprise administering to the cells certain compounds which inhibit the activity of an approximately 31 kD protease involved in beta-AP secretion. The 31 kD protease has been designated Cathepsin Y. Screening methods for beta-AP inhibitors rely on determining the activity of test compounds in the presence of Cathepsin Y and a suitable peptide substrate. This invention is also directed to a nucleic acid sequence that encodes Cathepsin Y and the expression and isolation of Cathepsin Y.

L25 ANSWER 2 OF 88 USPATFULL  
 ACCESION NUMBER: 1998-178936 USPATFULL  
 TITLE: Development of a PCR-based method for identification of Karnal bunt of wheat  
 INVENTOR(S): Smith, Oney P., Frederick, MD, United States  
 Peterson, Gary L., Walkersville, MD, United States  
 Beck, Raymond J., Frederick, MD, United States  
 Bond, Morris R., Middleburg, MD, United States  
 Schaad, Norman W., Myersville, MD, United States  
 PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)

NUMBER	DATE
--------	------



## United States (U.S. corporation)

Singh, Mohan Bir, Templestowe, Australia  
 Knox, Robert Bruce, North Balwyn, Australia  
 PATENT ASSIGNEE(S): The University of Melbourne, Parkville, Australia  
 (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 572069 980512

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Donaghue, Larry D.

LEGAL REPRESENTATIVE: Comley, Rose &amp; Tayon, Kivlin, B. Noel

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 66 Drawing Figure(s); 45 Drawing Page(s)

LINE COUNT: 11662

AB A superscalar microprocessor employing a way prediction structure is provided. The way prediction structure predicts a way of an associative cache in which an access will hit, and causes the data bytes from the typical tag comparisons to the request address are bypassed for data byte selection, causing the access time of the associative cache to be substantially the access time of the direct-mapped way prediction array within the way prediction structure. Also included in the way prediction structure is a way prediction control unit configured to update the way prediction array when an incorrect way prediction is detected. The clock cycle of the superscalar microprocessor, including the way prediction structure with its caches may be increased if the cache access time is limiting the clock cycle. Additionally, the associative cache may be retained in the high frequency superscalar microprocessor (which might otherwise employ a direct-mapped cache for access time reasons). Single clock cycle cache access to an associative data cache is maintained for high frequency operation.

L25 ANSWER 9 OF 88 USPATFULL  
 ACCESSION NUMBER: 1998-42213 USPATFULL  
 TITLE: DNA cycle sequencing  
 INVENTOR(S): Fuller, Carl W., Cleveland Heights, OH, United States  
 PATENT ASSIGNEE(S): Amersham Life Science, Inc., Cleveland, OH, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5741640 980421

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Jones, W. Gary

LEGAL REPRESENTATIVE: Rees, Dianne

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 25 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 736

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Method for sequencing DNA which includes the following steps: providing a polynucleotide primer complementary to a region of the DNA to be sequenced; providing the DNA to be sequenced, and contacting that primer and DNA together in the presence of a DNA polymerase and between 1 and 3 dNTPs, at least one of the dNTPs being labeled. The primer and DNA are contacted under conditions which allow extension of the primer by addition of one or more of the dNTPs to the primer to form an extended primer. The primer and DNA are then dissociated, generally by heating, and the contacting and dissociating steps repeated a plurality of times (usually 10-200 times). Finally, the extended primer is contacted with the DNA in the presence of a DNA polymerase which is generally the same polymerase as used in the initial labeling step) all four dNTPs and a chain terminating agent.

L25 ANSWER 10 OF 88 USPATFULL  
 ACCESSION NUMBER: 1998-36367 USPATFULL  
 TITLE: Allergenic proteins and peptides from johnson grass pollen  
 INVENTOR(S): Avijoglu, Asli, Towson, MD, United States

TITLE: Methods for normalizing numbers of lymphocytes  
 INVENTOR(S): Morozov, Yurachslav G., St. Petersburg, Russian Federation  
 Khavinson, Vladimir Kh., St. Petersburg, Russian Federation  
 PATENT ASSIGNEE(S): Cytoven J.V., Kirkland, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5736149 980407

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Nolan, Patrick T.

LEGAL REPRESENTATIVE: Lahive &amp; Cockfield, LLP, Mandragouras, Amy E.; Remillard, Jane E.

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1,8

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)

LINE COUNT: 1794

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halepense, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.

PATENT INFORMATION: US 95-470165 950606 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Chan, Christina Y.

LEGAL REPRESENTATIVE: Lahive &amp; Cockfield, LLP, Mandragouras, Amy E.;

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1,8

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)

LINE COUNT: 1794

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Tp.

NUMBER DATE

PATENT INFORMATION: SU 87-435283871230

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Faisse, Lila

LEGAL REPRESENTATIVE: Ungar, Susan

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 8309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Tp.

NUMBER DATE

PATENT INFORMATION: SU 87-435283871230

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Robinson, Randy R., Los Angeles, CA, United States

LEGAL REPRESENTATIVE: Liu, Alvin Y., OceanSide, CA, United States

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 8309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Tp.

NUMBER DATE

PATENT INFORMATION: SU 87-435283871230

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Feuerstein, Arnold H., Los Angeles, CA, United States

LEGAL REPRESENTATIVE: Better, Marc, Los Angeles, CA, United States

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 8309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Tp.

**AB** The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for peptidase signal peptide has been cloned on a plasmid to create a secretion "vector" which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion "vector" has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this "vector" have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.

L25 ANSWER 14 OF 88 USPATFULL  
ACCESSION NUMBER: 97:117911 USPATFULL

TITLE: Modular assembly of antibody genes, antibodies prepared thereby and use

INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United States

Horwitz, Arnold H., Los Angeles, CA, United States

Better, Marc, Los Angeles, CA, United States

Wall, Randolph, Sherman Oaks, CA, United States

Lei, Shui-Ping, Los Angeles, CA, United States

Wilcox, Gary L., Malibu, CA, United States

Patent Assignee(s): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

form.

NUMBER DATE

PATENT INFORMATION: US 5693493 971202

APPLICATION INFO.: US 95-450731 950525 (8)

RELATED APPLN. INFO.: Division of Ser. No. 94-299085, filed on 18 Aug 1994 which is a continuation of Ser. No. US 92-298755, filed on 8 Dec 1992, now abandoned

which is a continuation of Ser. No. US 90-501092, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-79380, filed on 11 Jan 1985, now abandoned said Ser. No. US 501092 which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ziska, Suzanne E.

LEGAL REPRESENTATIVE: Steine, Kassler, Goldstein & Fox P.L.L.C.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 63 Drawing Figure(s); 61 Drawing Page(s)

LINE COUNT: 4047

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for peptidase signal peptide has been cloned on a plasmid to create a secretion "vector" which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion "vector" has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this "vector" have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.

NUMBER DATE

PATENT INFORMATION: US 5698417 971216

APPLICATION INFO.: US 94-168203 950806 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 95-450731, filed on 25 May 1995 which is a division of Ser. No. US 94-299085, filed on 18 Aug 1994 which is a continuation of Ser. No. US 90-501092, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-79380, filed on 1 Nov 1985, now abandoned, said Ser. No. US 501092 which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ziska, Suzanne E.

LEGAL REPRESENTATIVE: Steine, Kassler, Goldstein & Fox, P.L.L.C.

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 63 Drawing Figure(s); 61 Drawing Page(s)

LINE COUNT: 4059

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for peptidase signal peptide has been cloned on a plasmid to create a secretion "vector" which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion "vector" has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this "vector" have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional

RELATED APPLN. INFO.: Division of Ser. No. US 92-971096, filed on 30 Oct 1992, now abandoned. Pat. No. US 5480972 DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Lau, Kawai

ASSISTANT EXAMINER:

LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP; Remillard, Jane E.; Mandragoras, Amy E.

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)

LINE COUNT: 1808

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halophenes, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments thereof of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.

L25 ANSWER 15 OF 88 USPATFULL  
ACCESSION NUMBER: 97:112329 USPATFULL

TITLE: Modular assembly of antibody genes, antibodies prepared thereby and use

INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United States

Horwitz, Arnold H., Los Angeles, CA, United States

Better, Marc, Los Angeles, CA, United States

Wall, Randolph, Sherman Oaks, CA, United States

Lei, Shui-Ping, Los Angeles, CA, United States

Wilcox, Gary L., Malibu, CA, United States

Patent Assignee(s): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5693493 971202

APPLICATION INFO.: US 95-450731 950525 (8)

RELATED APPLN. INFO.: Division of Ser. No. 94-299085, filed on 18 Aug 1994 which is a continuation of Ser. No. US 92-298755, filed on 8 Dec 1992, now abandoned

which is a continuation of Ser. No. US 90-501092, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-79380, filed on 1 Nov 1985, now abandoned, said Ser. No. US 501092 which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ziska, Suzanne E.

LEGAL REPRESENTATIVE: Steine, Kassler, Goldstein & Fox, P.L.L.C.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 63 Drawing Figure(s); 61 Drawing Page(s)

LINE COUNT: 4047

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional

fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for peptidase signal peptide has been cloned on a plasmid to create a secretion "vector" which is capable of producing a chosen protein which is transported across the bacterial membrane. The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halophenes, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments thereof of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.

L25 ANSWER 17 OF 88 USPATFULL  
ACCESSION NUMBER: 97:97739 USPATFULL

TITLE: Instruction format with sequentially performable operand address extension modification

INVENTOR(S): Sakamura, Ken, Tokyo, Japan

PATENT ASSIGNEE(S): Mitsubishi Denki Kabushiki Kaisha, Tokyo, Japan (part interest) a part interest

NUMBER DATE

PATENT INFORMATION: US 5680568 971021

APPLICATION INFO.: US 94-26031 940315 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 91-763473, filed on 20 Sep 1991, now abandoned which is a continuation of Ser. No. US 90-563749, filed on 3 Aug 1990, now abandoned which is a continuation of Ser. No. US 88-170972, filed on 21 Mar 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kuik, Paul V.

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 396 Drawing Figure(s); 211 Drawing Page(s)

LINE COUNT: 11450

AB A data processor which has an operand instruction having an operation code specifying portion to specify the kind of operation and an effective address specifying field showing the effective address of the operand, so that an additional mode specifying field to perform the extention in modification of addressing can be added to an addressing mode shown by the effective address specifying field, whereby even when the address modification calculation is carried out at multiple levels, the address

of the operand, thereby improving the execution speed of program and facilitating compiler structure.

L25 ANSWER 18 OF 88 USPATFULL  
ACCESSION NUMBER: 97:86430 USPATFULL

TITLE: Diagnostic applications of double D-loop

INVENTOR(S): Senna, Elisa P., Palo Alto, CA, United States

Calhoun, Cornelia J., San Francisco, CA, United States

Zartman, David A., Menlo Park, CA, United States

DaiKin Industries, Ltd., Osaka, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5619167 971125

APPLICATION INFO.: US 93-175096 931229 (8)

WO 9305178 930318  
APPLICATION INFO.: US 94-193317 940525 (8)  
VWO 92-JP113520/0904

APPLICATION INFO.: US 94-280617 940726 (8)

PATENT ASSIGNEE(S): FluidSense Corporation, Bedford, NH, United States (U.S. corporation)

NUMBER DATE

PRIORITY INFORMATION: JP 93-185324 930727

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: MacDonald, Allen R.

ASSISTANT EXAMINER: Rees, Dianne

LEGAL REPRESENTATIVE: Fabian, Gary R.; Stratford, Carol A.; Dehlinger, Peter J.

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 36 Drawing Figure(s); 17 Drawing Page(s)

LINE COUNT: 2639

CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB The present invention describes the formation of RecA protein catalyzed double-stranded probe/duplex linear target DNA complexes that are stable to deproteinization. The uses of this stable probe/target complex in diagnostic DNA detection systems in vitro and in situ DNA hybridization reactions is discussed. The probe/target complexes are also useful for diagnostic application in RecA protein facilitated DNA amplification reactions.

L25 ANSWER 19 OF 88 USPATFULL

TITLE: Methods and products for nucleic acid delivery

INVENTOR(S): Isner, Jeffrey M.; Weston, MA, United States

PATENT ASSIGNEE(S): St. Elizabeth's Medical Center of Boston, Inc., Boston, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5652225 970729

APPLICATION INFO.: US 96-675523 960703 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 94-318045, filed on 4 Oct 1994, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Low, Christopher S. F.

LEGAL REPRESENTATIVE: Conlin, David G.; Rasinick, David S. Dike, Bronstein, Robert & Cushman, LLP

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1314

CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB The present invention provides a method for the delivery of a nucleic acid to an arterial cell comprising contacting the cell with a hydrophilic polymer incorporating the nucleic acid. The nucleic acid may be any nucleic acid including antisense DNA or RNA. The nucleic acid may encode hormones, enzymes, receptors or drugs of therapeutic outcome. For example, in the treatment of ischemic diseases, one would select a DNA encoding an angiogenic protein. The nucleic acid may be carried by a microdelivery vehicle such as cationic liposomes and adenoviral \*\*\*vectors\*\*\*. DNA encoding different proteins may be used separately or simultaneously.

L25 ANSWER 20 OF 88 USPATFULL

TITLE: Speech efficient coding method

INVENTOR(S): Nishiguchi, Masayuki, Kanagawa, Japan

CHAN, Joseph, Tokyo, Japan

PATENT ASSIGNEE(S): Sony Corporation, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5630012 970513

APPLICATION INFO.: US 95-501092, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now

PATENT ASSIGNEE(S): FluidSense Corporation, Bedford, NH, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5624409 970429

APPLICATION INFO.: US 94-237872 940610 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Mendez, Manuel

LEGAL REPRESENTATIVE: Caseliro, Chris A.; Bohan, Thomas L.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1930

AB A dynamic controller for quantitatively rapid-pulse flow control over a wide dynamic range (1000x1) forms a fluid path from a pressurized source to a sink. The fluid path travels, typically in a disposable cassette, from the pressure source via a fast (one millisecond) on/off source control valve into a volume-displacement interface area, thence to a fast on/off feed control valve and on to the sink. The load control valve may be replaced by a passive flow restrictor where less dynamic range is required. From the reusable controller side, fast actuators are energized to open the normally-closed valves. A volume sensor mates with the volume-displacement interface area. This sensor uses an incompressible transfer fluid, typically different than and isolated from the deliverable fluid by membranes, to transmit volume displacement change into a transducer area for conversion from volume to a measurable electrical signal, typically a frequency. A known pressure/volume curve for the volume sensor allows pressure monitoring during operation, yielding knowledge of fluid source and load conditions.

A flow control method relies on a combination of very short, variable valve-open pulses and a design with comparatively large-diameter fluid passageways into the fluid capacitance of the volume sensor, to achieve flow limited more by inertia than viscosity. Distinct high-flow and low-flow control regimes are used. For high flow, bolus volume is maximized by pulsing for one-half the fluid oscillation period determined by the volume sensor fluid capacitance and the flow inertia of the fluid passageway, shutting off at flow reversal. For low flow, pulses typically below 10% of the high-flow pulse width yield small bolus volumes varying as the square of pulse width, providing control over a wide dynamic range of bolus sizes down to fractions of a microliter, permitting moderately high pulse frequencies even at very low average rates, achieving nearly continuous flow. Design with normally-closed, energize-to-open valves assures flow step if power is lost. In this context, the large fluid passageways lead to conserving energy and making battery operation practical.

L25 ANSWER 23 OF 88 USPATFULL

ACCESSION NUMBER: 97-39196 USPATFULL

TITLE: Method and apparatus for receiving and despread a continuous phase-modulated spread spectrum signal using self-synchronizing correlators

INVENTOR(S): Durant, Randolph L., Colorado Springs, CO, United States

Burbach, Mark, Peyton, CO, United States

Omnipoint Corporation, Colorado Springs, CO, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5627856 970506

APPLICATION INFO.: US 95-480442 9505067 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-30491, filed on 9 Sep 1994

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Chin, Stephen

ASSISTANT EXAMINER: Gluck, Jeffrey W.

LEGAL REPRESENTATIVE: Lyon & Lyon

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 9

NUMBER OF DRAWINGS: 49 Drawing Figure(s); 35 Drawing Page(s)

LINE COUNT: 3354

AB Apparatus and method for despreadng a received continuous phase modulated spread spectrum signal includes a power divider for dividing a received spread spectrum signal into a real signal and an imaginary signal. A real CPIM correlator demodulates the real signal into I and Q components and separately correlates the I component and the real Q component without generating a self-synchronizing correlation sequence, thereby performing self-synchronizing correlation. Likewise, an imaginary CPIM correlator demodulates the imaginary signal into I and Q components and separately correlates the imaginary I component and the imaginary Q component without generating a correlation sequence, thereby performing self-synchronizing correlation. The real I and imaginary I correlation signals are combined into a final I correlation signal, and the real Q and imaginary Q correlation signals are combined into a final Q correlation signal.

PATENT INFORMATION: US 5618920 970408

APPLICATION INFO.: US 94-235225 940429 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 92-870404, filed on 17 Apr 1992, now abandoned which is a division of Ser. No. US 90-501092, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now

NUMBER DATE

PATENT INFORMATION: US 5630012 970513

APPLICATION INFO.: US 90-501092, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now

DOCUMENT TYPE:	Utility	PRIMARY EXAMINER:	Walsh, Stephen G.
PRIMARY EXAMINER:	Budens, Robert D.	ASSISTANT EXAMINER:	Reeves, Julie E.
LEGAL REPRESENTATIVE:	Reeves, Julie E.	LEGAL REPRESENTATIVE:	Gucker, Stephen
NUMBER OF CLAIMS:	45	NUMBER OF CLAIMS:	Dreger, Walter H.
EXEMPLARY CLAIM:	1	NUMBER OF CLAIMS:	7
NUMBER OF DRAWINGS:	63	EXEMPLARIES CLAIM:	1
CAS INDEXING IS AVAILABLE FOR THIS PATENT:	3793	NUMBER OF DRAWINGS:	13
AB	The invention relates to the secretion of heavy chain immunoglobulin fragments and light chain immunoglobulins from prokaryotic hosts using a prokaryotic secretion signal peptide wherein the heavy chain fragments and light chains are capable of associating to form an antigen binding antibody fragment.	EXEMPLARIES CLAIM:	10 Drawing Page(s)
L25 ANSWER 24 OF 88 USPATFULL		PATENT INFORMATION:	US 5595898 970121
ACCESSION NUMBER:	9727917 USPATFULL	APPLICATION INFO.:	US 94-28905 940818 (8)
TITLE:	System for and method of recognizing and tracking target mark	RELATED APPLN. INFO.:	Continuation of Ser. No. US 92-387555, filed on 8 Dec. 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 29 Mar. 1990, now abandoned which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan. 1988, now abandoned And Ser. No. US 87-77528, filed on 24 Jul. 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-793580, filed on 1 Nov. 1985, now abandoned.
VENTOR(S):	Hasegawa, Fumi, Kawasaki, Japan Okabayashi, Kaiji, Kawasaki, Japan Watanabe, Ichiro, Kawasaki, Japan Kanda, Shinji, Kawasaki, Japan Sawasaki, Naoyuki, Kawasaki, Japan Murase, Yuchi, Kawasaki, Japan	DOCUMENT TYPE:	Utility
PATENT ASSIGNEE(S):	Fujitsu Limited, Kawasaki, Japan (non-U.S. corporation)	PRIMARY EXAMINER:	Ziska, Suzanne E.
		LEGAL REPRESENTATIVE:	Steene, Kessler, Goldstein, & Fox
		NUMBER OF CLAIMS:	4
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	64 Drawing Figure(s); 61 Drawing Page(s)
		LINE COUNT:	3691
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.	PATENT INFORMATION:	US 5590323 961231
L25 ANSWER 24 OF 88 USPATFULL		APPLICATION INFO.:	US 94-24256 940513 (8)
ACCESSION NUMBER:	9727917 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	System for and method of recognizing and tracking target mark	RELATED APPLN. INFO.:	Continuation of Ser. No. US 92-119228, filed on 28 Sep. 1993, now patented, Pat. No. US 5521843
VENTOR(S):	Hasegawa, Fumi, Kawasaki, Japan Okabayashi, Kaiji, Kawasaki, Japan Watanabe, Ichiro, Kawasaki, Japan Kanda, Shinji, Kawasaki, Japan Sawasaki, Naoyuki, Kawasaki, Japan Murase, Yuchi, Kawasaki, Japan	DOCUMENT TYPE:	Utility
PATENT ASSIGNEE(S):	Fujitsu Limited, Kawasaki, Japan (non-U.S. corporation)	PRIMARY EXAMINER:	Ziska, Suzanne E.
		LEGAL REPRESENTATIVE:	Steene, Kessler, Goldstein, & Fox
		NUMBER OF CLAIMS:	4
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	64 Drawing Figure(s); 61 Drawing Page(s)
		LINE COUNT:	3691
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	The invention also relates to DNA coding for peptidase lyase signal peptide has been cloned on a plasmid to create a secretion vector*** which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector*** has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this ***vector*** have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.	PATENT INFORMATION:	US 5593844 970114
L25 ANSWER 24 OF 88 USPATFULL		APPLICATION INFO.:	US 95-441357 950515 (8)
ACCESSION NUMBER:	97363 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Ligand-mediated immunoaffunctional hormone binding protein assay method	RELATED APPLN. INFO.:	Continuation of Ser. No. US 95-408094, filed on 21 Mar. 1995 which is a continuation of Ser. No. US 83-3963, filed on 9 Apr. 1983, now abandoned
VENTOR(S):	Carlsson, Lena M. S., Gothenburg, Sweden	DOCUMENT TYPE:	Utility
PATENT ASSIGNEE(S):	Clark, G., Pacific, CA, United States Wong, Wai L. T., Los Altos, CA, United States Genentech, Inc., San Francisco, CA, United States (U.S. corporation)	PRIMARY EXAMINER:	Armstrong, William, McLeod, & Naughton
		ASSISTANT EXAMINER:	Peeso, Thomas
		LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hatton, McLeland & Naughton
		NUMBER OF CLAIMS:	20
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	109 Drawing Figure(s); 47 Drawing Page(s)
		LINE COUNT:	2225
AB	A system for and a method of recognizing and tracking a target mark with a video camera is disclosed. The system includes a target mark (10) disposed on an object (11) and composed of a black circle and a white triangle mounted centrally on the black circle and three-dimensionally shifted from the black circle, a video camera (20) for imaging the target mark (10), a robot (30) supporting the video camera (20) and movable in directions with six degrees of freedom, an image processor (40) for processing image data of the target mark which is produced by the video camera (20), a shift calculating unit (50) for detecting a shift of the target mark (10) from projected histogram information of the target mark (10) which is produced by the image processor (40), and a robot controller (60) for controlling movement of the robot depending on the shift to enable the video camera (20) to track the target mark (10). The system is capable of tracking the target mark (10) attached to the object (11) on a real-time basis. Mark recognizing apparatus capable of accurately recognizing target marks of other shapes is also disclosed.	PATENT INFORMATION:	US 5593844 970114
L25 ANSWER 24 OF 88 USPATFULL		APPLICATION INFO.:	US 95-441357 950515 (8)
ACCESSION NUMBER:	97112100 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Method and apparatus for focus control of transmit and receive beamformer systems	RELATED APPLN. INFO.:	Continuation of Ser. No. US 90-615538, filed on 19 Nov. 1990, now patented, Pat. No. US 5210717
VENTOR(S):	Gee, Albert, Los Altos, CA, United States	PRIMARY EXAMINER:	Christopher R., Cupertino, CA, United States
		ASSISTANT EXAMINER:	Cooley, Christopher R., Cupertino, CA, United States
		LEGAL REPRESENTATIVE:	Christopher R., Cupertino, CA, United States
		NUMBER OF CLAIMS:	1
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	13 Drawing Figure(s); 10 Drawing Page(s)
		LINE COUNT:	2317
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	A ligand-mediated immunoaffunctional assay (LIFA) method for detecting the presence and the concentration of polypeptides hormones binding proteins which comprises capturing the binding protein with a solid phase bound first antibody saturating the bound hormone binding protein with the ligand polypeptide hormones, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound to the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulations of growth hormone binding protein, growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein are disclosed.	PATENT INFORMATION:	US 5590323 961231
L25 ANSWER 27 OF 88 USPATFULL		APPLICATION INFO.:	US 94-24256 940513 (8)
ACCESSION NUMBER:	98121716 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Optimal parallel processor architecture for real time multitasking	RELATED APPLN. INFO.:	Continuation of Ser. No. US 92-387555, filed on 8 Dec. 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 29 Mar. 1990, now abandoned which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan. 1988, now abandoned And Ser. No. US 87-77528, filed on 24 Jul. 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-793580, filed on 1 Nov. 1985, now abandoned.
VENTOR(S):	Karlaftopoulos, Stamatios V., Clinton Township, Hunterdon County, NJ, United States	PRIMARY EXAMINER:	Oberley, Alvin E.
PATENT ASSIGNEE(S):	Lucent Technologies Inc., Murray Hill, NJ, United States (U.S. corporation)	ASSISTANT EXAMINER:	Banankhah, Majid
		NUMBER OF CLAIMS:	3
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	5 Drawing Figure(s); 2 Drawing Page(s)
		LINE COUNT:	612
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.	PATENT INFORMATION:	US 5593844 970114
L25 ANSWER 26 OF 88 USPATFULL		APPLICATION INFO.:	US 95-441357 950515 (8)
ACCESSION NUMBER:	97363 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Ligand-mediated immunoaffunctional hormone binding protein assay method	RELATED APPLN. INFO.:	Continuation of Ser. No. US 95-408094, filed on 21 Mar. 1995 which is a continuation of Ser. No. US 83-3963, filed on 9 Apr. 1983, now abandoned
VENTOR(S):	Carlsson, Lena M. S., Gothenburg, Sweden	DOCUMENT TYPE:	Utility
PATENT ASSIGNEE(S):	Clark, G., Pacific, CA, United States Wong, Wai L. T., Los Altos, CA, United States Genentech, Inc., San Francisco, CA, United States (U.S. corporation)	PRIMARY EXAMINER:	Armstrong, William, McLeod, & Naughton
		ASSISTANT EXAMINER:	Peeso, Thomas
		LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hatton, McLeland & Naughton
		NUMBER OF CLAIMS:	20
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	109 Drawing Figure(s); 47 Drawing Page(s)
		LINE COUNT:	2225
AB	A system for and a method of recognizing and tracking a target mark with a video camera is disclosed. The system includes a target mark (10) disposed on an object (11) and composed of a black circle and a white triangle mounted centrally on the black circle and three-dimensionally shifted from the black circle, a video camera (20) for imaging the target mark (10), a robot (30) supporting the video camera (20) and movable in directions with six degrees of freedom, an image processor (40) for processing image data of the target mark which is produced by the video camera (20), a shift calculating unit (50) for detecting a shift of the target mark (10) from projected histogram information of the target mark (10) which is produced by the image processor (40), and a robot controller (60) for controlling movement of the robot depending on the shift to enable the video camera (20) to track the target mark (10). The system is capable of tracking the target mark (10) attached to the object (11) on a real-time basis. Mark recognizing apparatus capable of accurately recognizing target marks of other shapes is also disclosed.	PATENT INFORMATION:	US 5593844 970114
L25 ANSWER 26 OF 88 USPATFULL		APPLICATION INFO.:	US 95-441357 950515 (8)
ACCESSION NUMBER:	97112100 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Method and apparatus for focus control of transmit and receive beamformer systems	RELATED APPLN. INFO.:	Continuation of Ser. No. US 90-615538, filed on 19 Nov. 1990, now patented, Pat. No. US 5210717
VENTOR(S):	Gee, Albert, Los Altos, CA, United States	PRIMARY EXAMINER:	Christopher R., Cupertino, CA, United States
		ASSISTANT EXAMINER:	Cooley, Christopher R., Cupertino, CA, United States
		LEGAL REPRESENTATIVE:	Christopher R., Cupertino, CA, United States
		NUMBER OF CLAIMS:	1
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	13 Drawing Figure(s); 10 Drawing Page(s)
		LINE COUNT:	2317
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	A ligand-mediated immunoaffunctional assay (LIFA) method for detecting the presence and the concentration of polypeptides hormones binding proteins which comprises capturing the binding protein with a solid phase bound first antibody saturating the bound hormone binding protein with the ligand polypeptide hormones, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound to the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulations of growth hormone binding protein, growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein are disclosed.	PATENT INFORMATION:	US 5590323 961231
L25 ANSWER 27 OF 88 USPATFULL		APPLICATION INFO.:	US 94-24256 940513 (8)
ACCESSION NUMBER:	98121716 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Optimal parallel processor architecture for real time multitasking	RELATED APPLN. INFO.:	Continuation of Ser. No. US 92-387555, filed on 8 Dec. 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 29 Mar. 1990, now abandoned
VENTOR(S):	Karlaftopoulos, Stamatios V., Clinton Township, Hunterdon County, NJ, United States	PRIMARY EXAMINER:	Oberley, Alvin E.
PATENT ASSIGNEE(S):	Lucent Technologies Inc., Murray Hill, NJ, United States (U.S. corporation)	ASSISTANT EXAMINER:	Banankhah, Majid
		NUMBER OF CLAIMS:	3
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	5 Drawing Figure(s); 2 Drawing Page(s)
		LINE COUNT:	612
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	The invention relates to a parallel processor system having the minimum number of microprocessors necessary such that execution of a set of tasks of a multi-tasking application such that execution of an activity of a second task. The process includes the step of selecting an initial number of microprocessors for executing the application in real-time. The selecting step includes placing in a second column of the matrix, assigning a priority p sub i to each task p sub i, where i is between 0 and 1, subdividing at least one of the tasks into discrete activities, each of the activities having a corresponding execution time t sub i, estimating the execution time for each activity, reducing the number of rows in the matrix by grouping together tasks having activities that can be executed within a predetermined time window T, and providing a plurality of task subsets, each subset having a maximum number of interdependent tasks and the number of subsets corresponding to the initial number of microprocessors. The inventive process further includes the steps of listing dependencies between rows in a second column of the matrix, assigning a priority p sub i to each task p sub i, where i is between 0 and 1, subdividing at least one of the tasks into discrete activities, each of the activities having a corresponding execution time t sub i, estimating the execution time for each activity, reducing the number of rows in the matrix by grouping together tasks having activities that can be executed within a predetermined time window T, and providing a number of microprocessors corresponding to the number of rows obtained from the rows reducing step.	PATENT INFORMATION:	US 5590323 961231
L25 ANSWER 28 OF 88 USPATFULL		APPLICATION INFO.:	US 94-24256 940513 (8)
ACCESSION NUMBER:	97112100 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Method and apparatus for focus control of transmit and receive beamformer systems	RELATED APPLN. INFO.:	Continuation of Ser. No. US 90-615538, filed on 19 Nov. 1990, now patented, Pat. No. US 5210717
VENTOR(S):	Gee, Albert, Los Altos, CA, Cupertino, CA, United States	PRIMARY EXAMINER:	Christopher R., Cupertino, CA, United States
		ASSISTANT EXAMINER:	Cooley, Christopher R., Cupertino, CA, United States
		LEGAL REPRESENTATIVE:	Christopher R., Cupertino, CA, United States
		NUMBER OF CLAIMS:	1
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	13 Drawing Figure(s); 10 Drawing Page(s)
		LINE COUNT:	2317
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	A ligand-mediated immunoaffunctional hormone binding protein assay method	PATENT INFORMATION:	US 5593844 970114
L25 ANSWER 28 OF 88 USPATFULL		APPLICATION INFO.:	US 95-441357 950515 (8)
ACCESSION NUMBER:	97112100 USPATFULL	DOCUMENT TYPE:	Utility
TITLE:	Method and apparatus for focus control of transmit and receive beamformer systems	RELATED APPLN. INFO.:	Continuation of Ser. No. US 90-615538, filed on 19 Nov. 1990, now patented, Pat. No. US 5210717
VENTOR(S):	Gee, Albert, Los Altos, CA, Cupertino, CA, United States	PRIMARY EXAMINER:	Christopher R., Cupertino, CA, United States
		ASSISTANT EXAMINER:	Cooley, Christopher R., Cupertino, CA, United States
		LEGAL REPRESENTATIVE:	Christopher R., Cupertino, CA, United States
		NUMBER OF CLAIMS:	1
		EXEMPLARIES CLAIM:	1
		NUMBER OF DRAWINGS:	13 Drawing Figure(s); 10 Drawing Page(s)
		LINE COUNT:	2317
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

PATENT ASSIGNEE(S): Acuson Corporation, Mountain View, CA, United States (U.S. corporation)

these \*\*\*vectors\*\*\* have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.

NUMBER DATE

PATENT INFORMATION: US 55891517 961203

APPLICATION INFO.: US 95-432544 950502 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-286268,

filed on 5 Aug 1994, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Phatak, Daniel T.

LEGAL REPRESENTATIVE: Brinks Hofer Gilson & Lione

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 30 Drawing Figure(s); 24 Drawing Page(s)

LINE COUNT: 4842

AB A beamformer control system includes a primary control and secondary controls so that delay and apodization beamformation profits can be generated on a dynamic and distributed basis with sparsely sampled base delay and apodization data sets first; expanded to the final values by the primary control and then further expanded in the secondary controls associated with multi-processing channels of the beamformer systems. The beamformer control system coordinates the transmit and receive beamformer systems preferably using data sets common to all beamformer systems, and by advantageously specifying to all beamformer systems, processing mode trade-offs among the signal nominal center frequency, the range spatial resolution, and the number of beams. The beamformer control system supports multiple simultaneous beam operation, as well as beam-to-beam adjustable frequency and synthetic aperture operations. Further, the present beamformer control system maintains beam-to-beam coherent receive beamformation and supports adaptive beamformation.

L25 ANSWER 29 OF 88 USPATFULL

ACCESSION NUMBER: 96106368 USPATFULL

TITLE: \*\*\*Vectors\*\*\* with peptide lysine signal

INVENTOR(S): Robinson, Randy R., Walnut Creek, CA, United States

Bentari, Marc, Los Angeles, CA, United States

Lai, Shau-Ping, Los Angeles, CA, United States

Wilcock, Gary L., Mill Creek, WA, United States

PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5576196 961119

APPLICATION INFO.: US 94-357234 941209 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 93-20671, filed on 22 Feb 1993, now abandoned which is a division of

Ser. No. US 92-587555, filed on 8 Dec 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 29 Mar 1990, now abandoned

which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned

which is a continuation-in-part of Ser. No. US 85-73380, filed on 1 Nov 1985, now abandoned,

which is a continuation-in-part of Ser. No. US 80-501092, filed on 29 Mar 1990

which is a continuation-in-part of Ser. No. US 83-142039, filed on 11 Jan 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Mosher, May E.

LEGAL REPRESENTATIVE: Sterns, Kassler, Goldstein & Fox P.L.L.C.

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 58 Drawing Figure(s); 50 Drawing Page(s)

LINE COUNT: 3860

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to DNA coding for a peptidase lyase signal \*\*\*vectors\*\*\* which are inserted into plasmids to create secretory directing transport across the bacterial membrane. The secretion \*\*\*vectors\*\*\* have been used to secrete extracellular thaumatin and extracellular antibody fragments. The proteins produced by included. Isolated peptide cofactors of adenovirus proteinases are further

activity, methods of purifying and identifying said peptide cofactors are also described. Antibodies immunoreactive with adenovirus proteinases, immunospecific antibodies, and methods for preparing them are also described. Other related methods and materials are also described.

L25 ANSWER 32 OF 88 USPATFULL

ACCESSION NUMBER: 96102489 USPATFULL

TITLE: Method and system for process expression and resolution including a general method of direct association

INVENTOR(S): Fant, Karl M., Minneapolis, MN, United States

PATENT ASSIGNEE(S): Theseus Research, Inc., Minneapolis, MN, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 55727232 961105

APPLICATION INFO.: US 94-2986809 940826 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 92-837641, filed on 12 Feb 1992, now patented, Pat. No. US 5355346

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kulk, Paul V.

LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Weiler & Schmidt, P.A.

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 68 Drawing Figure(s); 27 Drawing Page(s)

LINE COUNT: 6077

AB A method and system for process expression and resolution including a general method of direct association is described. A first language structure including a named result reference which is a destination for a result string for a directly associated invocation. In addition, a second language structure including a result link is provided. A first end of the result link is located within a formal list of a definition. A second end of the result link is directly associated by list position and is located within an actual list of an invocation. A third language structure including the resultant is provided. The resultant is associated with one or more language elements, including: the correspondingly named result reference and/or the correspondingly named result link. A resolution mechanism replaces the named result reference associated with the string such that a language expression is resolved.

L25 ANSWER 31 OF 88 USPATFULL

ACCESSION NUMBER: 9670309 USPATFULL

TITLE: Co-factor activated recombinant adenovirus proteinases

INVENTOR(S): Anderson, Carl W., Stony Brook, NY, United States

Mangal, Walter F., Shoreham, NY, United States

PATENT ASSIGNEE(S): Associated Universities, Inc., Washington, DC, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 554264 960806

APPLICATION INFO.: US 93-155171 931119 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 92-851217, filed on 13 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 90-545585, filed on 28 Jun 1990, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Wax, Robert A.

ASSISTANT EXAMINER: Moore, William W.

LEGAL REPRESENTATIVE: Bogosian, Margaret C.

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Figure(s); 25 Drawing Page(s)

LINE COUNT: 3005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application describes methods and expression constructs for producing activatable recombinant adenovirus proteinases. Purified \*\*\*vectors\*\*\* which are capable of producing a chosen protein by directing transport across the bacterial membrane. The secretion \*\*\*vectors\*\*\* have been used to secrete extracellular thaumatin and extracellular antibody fragments. The proteins produced by included. Isolated peptide cofactors of adenovirus proteinases are further

L25 ANSWER 34 OF 88 USPATFULL

ACCESSION NUMBER: 9646894 USPATFULL

TITLE: System for and method of recognizing and tracking target mark

INVENTOR(S): Hashima, Masayoshi, Kawasaki, Japan  
Hasagawa, Fumi, Kawasaki, Japan

Okabayashi, Kenji Kawasaki, Japan  
Watanabe, Ichiro, Kawasaki, Japan  
Kanda, Shinji, Kawasaki, Japan  
Sawasaki, Naoyuki, Kawasaki, Japan  
Murase, Yuichi, Kawasaki, Japan  
**PATENT ASSIGNEE(S):** Fujitsu Limited, Kawasaki, Japan (non-U.S. corporation)

**PATENT ASSIGNEE(S):** Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

**PRIORITY INFORMATION:** US 5521843 960528  
WO 9315376 930805  
APPLICATION INFO.: US 93-119228 930928 (8)  
(WO 93-IP107 930129  
930928 PCT 102(e) date  
930928 PCT 102(e) date)

**PRIORITY INFORMATION:** IP 92-15557 920130  
JP 92-193457 920626  
JP 92-219029 920818  
JP 92-291628 921029  
JP 92-307015 921117  
**DOCUMENT TYPE:** Utility  
**PRIMARY EXAMINER:** Voeltz, Emanuel T.  
**ASSISTANT EXAMINER:** Peaseo, Thomas  
**LEGAL REPRESENTATIVE:** Armstrong, Westerman, Hattori, McElland & Naughton

NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 109 Drawing Figure(s); 47 Drawing Page(s)

LINE COUNT: 2168

**AB** A system for and a method of recognizing and tracking a target mark with a video camera is disclosed. The system includes a target mark (10) disposed on an object (1) and composed of a black circle and a white triangle mounted centrally on the black circle and three-dimensionally shifted from the black circle, a video camera (20) for imaging the target mark (10), a robot (30) supporting the video camera (20) and movable in directions with six degrees of freedom, an image processor (40) for processing image data of the target mark which is produced by the video camera (20), a shift calculating unit (50) for detecting a shift of the target mark (10) from projected histogram information of the target mark (10) which is produced by the image processor (40), and a robot controller (60) for controlling the movement of the robot depending on the shift to enable the video camera (20) to track the target mark (10). The system is capable of tracking the target mark (20) attached to the object (1) on a real-time basis. Mark recognizing apparatus capable of accurately recognizing target marks of other shapes is also disclosed.

**25 ANSWER 35 OF 88 USPATFULL**  
**ACCESSION NUMBER:** 96:37207 USPATFULL  
**TITLE:** High speed simulcast data system using adaptive compensation  
**INVENTOR(S):** Marchetto, Robert F., Burnaby, Canada  
Ho, Paul K., Surrey, Canada  
**PATENT ASSIGNEE(S):** Glaryay Electronics, Inc., Charlotte, NC, United States (U.S. corporation)

**NUMBER OF CLAIMS:** 15  
**EXEMPLARY CLAIM:** 1

NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)

**AB** In a simulcast communication system, a method and apparatus for compensating differences in propagation time, lack of synchronization in transmitters, and multipath fading to recover

data transmitted to a receiving device. In a simulcast communication system(20) that comprises a plurality of transmitters (32), a receiver (36) that includes a digital signal processor (DSP) (86) that processes a demodulated received signal to adaptively compensate for changes in the channel through which a multipath signal is propagated from the transmitters to the receiver. In one embodiment, the DSP comprises a decision feedback equalizer. An error signal is produced by the equalizer through a comparison of the estimated symbols with symbols most likely transmitted, for use in updating filter coefficients used by the equalizer in processing the received signal. Alternatively, in a linear adaptive equalizer, reference or pilot symbols transmitted with the data symbols are used to determine the error signal. Another embodiment implements a Viterbi algorithm to make decisions of the most likely data symbols in response to estimates of the channel impulse response. Further, a hybrid embodiment combines the Viterbi decoder with a bi-directional decision feedback equalizer that produces forward and reverse estimates of the sequence of data symbols. The Viterbi decoder selects between the forward and reverse sequences based upon channel impulse response estimates to dynamically compensate for varying channel conditions. Using any one of these embodiments, a linear modulated signal can be decoded to recover the data transmitted, even though the received signal has been degraded by propagation in a multipath fading channel. The same techniques are also disclosed as applicable to constant envelope modulated transmissions in a simulcast system.

**L25 ANSWER 36 OF 88 USPATFULL**  
**ACCESSION NUMBER:** 96:13003 USPATFULL  
**TITLE:** BCR/ABL transgenic animals as models for Philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia  
**INVENTOR(S):** Groffman, John, Los Angeles, CA, United States  
Heisterkamp, Nora, Los Angeles, CA, United States  
Pattengale, Paul K., Los Angeles, CA, United States  
**PATENT ASSIGNEE(S):** Childrens Hospital of Los Angeles, Los Angeles, CA, United States (U.S. corporation)

**NUMBER DATE**

**PATENT INFORMATION:** US 5491283 960213  
APPLICATION INFO.: US 93-3951 930114 (8)  
RELATED APPL. INFO.: Continuation of Ser. No. US 89-440682, filed on 22 Nov 1989, now abandoned  
**DOCUMENT TYPE:** Utility  
**PRIMARY EXAMINER:** Chambers, Jasemine C.  
**LEGAL REPRESENTATIVE:** Pennie & Edmonds  
**NUMBER OF CLAIMS:** 15  
**EXEMPLARY CLAIM:** 1  
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)  
LINE COUNT: 1016  
**CAS INDEXING IS AVAILABLE FOR THIS PATENT.**

**AB** The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In a preferred embodiment of the present invention, the transgenic animals exhibit a rapid induction of acute leukemia.

The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome and which develops leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a better understanding of CML and ALL and in developing effective therapeutic regimens.

**26 ANSWER 37 OF 88 USPATFULL**  
**ACCESSION NUMBER:** 96:13933 USPATFULL  
**TITLE:** Positional deviation detecting method  
**INVENTOR(S):** Matsugu, Masakazu, Tokyo, Japan  
Saiochi, Kenji, Yokohama, Japan  
Hatori, Jun, Zama, Japan  
Houryu, Sakae, Hachioji, Japan

**NUMBER OF CLAIMS:** 9  
**EXEMPLARY CLAIM:** 1

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)

**AB** The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h 1, a major allergen of Sorghum halepense, and fragments thereof. The present invention also provides purified Sor h 1 or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h 1, or at least one fragment thereof and fragments of Sor h 1 prepared synthetically. Sor h 1 and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.

L25 ANSWER 41 OF 88 USPATFULL ACCESSION NUMBER: 95:89031 USPATFULL TITLE: Method for solving geometric constraint systems INVENTOR(S): Kramer, Glenn A., Austin, TX, United States Keyroud, Walid T., Austin, TX, United States Pabon, Jahir A., Austin, TX, United States PATENT ASSIGNEE(S): Schlumberger Technology Corporation, Austin, TX, United States (U.S. corporation)	NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s) LINE COUNT: 429 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB Residual levels of monomeric ethylenically unsaturated carboxylic acid esters such as allyl acrylate and methacrylates, especially ethyl, butyl and "iso-hexyl" acrylates and methacrylates, in surfactant stabilised dispersions of polymers of the monomer(s) such as latexes or products formulated from latexes, are reduced by treatment with a hydrolytic enzyme, particularly a lipase or esterase. The treatment reduces and can obviate the perceived bad odour of the dispersions arising from the presence of the monomers.
L25 ANSWER 43 OF 88 USPATFULL ACCESSION NUMBER: 95:23410 USPATFULL TITLE: Edge detecting apparatus INVENTOR(S): Aoyama, Chiaki, Wako, Japan PATENT ASSIGNEE(S): Honda Giken Kogyo Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)	NUMBER OF DRAWINGS: 12 Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 354 PRIORITY INFORMATION: JP 92-103244 920422 DOCUMENT TYPE: Utility PRIMARY EXAMINER: Bourreau, Leo H. ASSISTANT EXAMINER: Cammarata, Michael R. LEGAL REPRESENTATIVE: Lyon & Lyon NUMBER OF CLAIMS: 5 EXEMPLARY CLAIM: AB Edge detecting masks each having a sensing directivity to a specific direction are arranged with each directivity direction shifted by a given angular interval from the neighboring masks. A sum-of-products computation is performed between weighting elements in each of the so-arranged masks and image data indicating the brightness or tint of respective pixels. A selecting device selects a mask which exhibits the maximum sum-of-products output value among others and also selects two or three more masks before and behind the selected mask according to the interpolation method employed. An estimate computing device performs interpolation using the outputs of the selected edge detecting masks to estimate a true edge direction.
L25 ANSWER 44 OF 88 USPATFULL ACCESSION NUMBER: 94:113648 USPATFULL TITLE: Wavelength converting optical device INVENTOR(S): Hatakoshi, Genichi, Yokohama, Japan Okajima, Masaki, Kawasaki, Japan Terashima, Kazutaka, Ebina, Japan Usanatu, Yutaka, Yokohama, Japan PATENT ASSIGNEE(S): Kabushiki Kaisha Toshiba, Kawasaki, Japan (non-U.S. corporation)	NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s) LINE COUNT: 354 PRIORITY INFORMATION: 12 Drawing Figure(s); 8 Drawing Page(s) NUMBER OF CLAIMS: 1 EXEMPLARY CLAIM: AB Edge detecting masks each having a sensing directivity to a specific direction are arranged with each directivity direction shifted by a given angular interval from the neighboring masks. A sum-of-products computation is performed between weighting elements in each of the so-arranged masks and image data indicating the brightness or tint of respective pixels. A selecting device selects a mask which exhibits the maximum sum-of-products output value among others and also selects two or three more masks before and behind the selected mask according to the interpolation method employed. An estimate computing device performs interpolation using the outputs of the selected edge detecting masks to estimate a true edge direction.
L25 ANSWER 45 OF 88 USPATFULL ACCESSION NUMBER: 95:50093 USPATFULL TITLE: Decomposition of ethylenically unsaturated carboxylic esters INVENTOR(S): Nicks, Peter F., Maidenhead, Great Britain Carber, Mark A., Stockton on Tees, Great Britain Reillon, Julian M., Darlington, Great Britain PATENT ASSIGNEE(S): Imperial Chemical Industries plc, London, United Kingdom (non-U.S. corporation)	NUMBER OF DRAWINGS: 15 Drawing Figure(s); 16 Drawing Page(s) LINE COUNT: 1577 AB A method, useful in computer-aided design, for finding possible configurations of a system having a collection of geometric entities and constraints. The method represents the geometric entities in terms of degrees of freedom and systematically satisfies the constraints reducing the degrees of freedom of the geometric entities. The method uses a number of specialized routines, called plan fragments, which satisfy a particular constraint relating to a particular geometric entity. Each plan fragment changes the configuration of a geometric entity in space—i.e. the location and orientation—satisfying a constraint and reducing a degree of freedom. The series of plan fragments comprise an assembly plan for possible configurations of the system. The method identifies overconstrained, fully constrained, and underconstrained systems to the user and assists in finding possible configurations if the constraints are changed, added, or deleted. The method is useful in solving any geometric constraint problem, such as describing mechanical assemblies constraint-based sketching and design, geometric modeling for CAD, and kinematic analysis of robots and linkage mechanisms. By reasoning symbolically about the geometry of the system, the method provides faster solutions, numerical stability, user feedback, and the ability to handle redundant constraints.
L25 ANSWER 46 OF 88 USPATFULL ACCESSION NUMBER: 95:111065 USPATFULL TITLE: Ultrasonic measuring system INVENTOR(S): Kuzuya, Naoya, Japan Nakahara, Naoyuki, Japan Aoki, Yasuyuki, Ovarasaki, Japan PATENT ASSIGNEE(S): Aisin Seiki Kabushiki Kaisha, Kariya, Japan (non-U.S. corporation)	NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s) LINE COUNT: 982 AB An ultrasonic measuring system for a vehicle is composed of first and second ultrasonic transducing assemblies TR1 and TR2. Each transducing assembly TR1, TR2 has three ultrasonic transducers TR11, TR12, TR13, TR21, TR22, TR23 which are separated from each other at an angle of 120 degrees in a horizontal plane about axis disposed at front and a rear of the vehicle, respectively. Each transducer transmits ultrasonic waves to a road surface at a predefined down-angle relative to the road surface and receives reflected waves from the road surface. Each of the transducers TR21, TR22, TR23 transmits ultrasonic waves to the road surface and receiving reflected waves from the road surface in an opposite direction to a corresponding one of the transducers TR11, TR12, TR13. A two dimensional speed, a yaw rate and a yawing center are obtained by differences of first three speed "vectors" in three directions obtained by the first ultrasonic transducing assembly TR1 and second three speed "vectors" in second three directions, corresponding to the first three directions, obtained by the second ultrasonic transducing assembly TR2.
PRIORITY INFORMATION: JP 93-122987 930525 DOCUMENT TYPE: Utility PRIMARY EXAMINER: Ramírez, Ellis B. ASSISTANT EXAMINER: Peso, Thomas LEGAL REPRESENTATIVE: Sugirth, Mion, Zinn, Macpeak & Seas NUMBER OF CLAIMS: 8 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s) LINE COUNT: 982 AB An ultrasonic measuring system for a vehicle is composed of first and second ultrasonic transducing assemblies TR1 and TR2. Each transducing assembly TR1, TR2 has three ultrasonic transducers TR11, TR12, TR13, TR21, TR22, TR23 which are separated from each other at an angle of 120 degrees in a horizontal plane about axis disposed at front and a rear of the vehicle, respectively. Each transducer transmits ultrasonic waves to a road surface at a predefined down-angle relative to the road surface and receives reflected waves from the road surface. Each of the transducers TR21, TR22, TR23 transmits ultrasonic waves to the road surface and receiving reflected waves from the road surface in an opposite direction to a corresponding one of the transducers TR11, TR12, TR13. A two dimensional speed, a yaw rate and a yawing center are obtained by differences of first three speed "vectors" in three directions obtained by the first ultrasonic transducing assembly TR1 and second three speed "vectors" in second three directions, corresponding to the first three directions, obtained by the second ultrasonic transducing assembly TR2.	NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 1452 AB A wavelength converting optical device includes an optical waveguide which has a waveguide portion and a cladding portion, at
PRIORITY INFORMATION: GB 90-7140 900330 DOCUMENT TYPE: Utility PRIMARY EXAMINER: Schäfer, Joseph L. ASSISTANT EXAMINER: Weber, Tom LEGAL REPRESENTATIVE: Cushman Darby & Cushman NUMBER OF CLAIMS: 6 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 43 Drawing Figure(s); 43 Drawing Page(s) LINE COUNT: 123 AB A wavelength converting optical device	NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s) LINE COUNT: 1452 AB A wavelength converting optical device includes an optical waveguide which has a waveguide portion and a cladding portion, at

least one of which is formed of a nonlinear optical material. A fundamental wave, incident on the waveguide portion from an input end face of the waveguide, is converted into an optical second harmonic wave by Cerenkov radiation and is radiated into the cladding portion. The radiated second harmonic wave is output from an output end face of the waveguide. A reflecting film is provided on the emerging end face of the waveguide. The reflecting film includes a high reflectivity with respect to the fundamental wave of a guide mode and a low reflectivity with respect to the optical second harmonic wave. A wave front converting element is arranged to oppose the reflecting film. The converting element has a diffraction grating for converting the second harmonic wave, emerging from the output end face of the waveguide, into a plane wave.

L25 ANSWER 45 OF 88 USPATFULL  
ACCESSION NUMBER: 94:37932 USPATFULL  
TITLE: Method and apparatus for encoding-decoding a digital signal  
INVENTOR(S): Duhame, Pierre, Issy les Moulineaux, France  
PATENT ASSIGNEE(S): France Telecom, Paris, France (non-U.S. corporation)

NUMBER	DATE
PATENT INFORMATION: US 5363096 941108 APPLICATION INFO.: US 92-871543 920421 (7)	

PRIORITY INFORMATION: FR 91-5064 910424  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Logan, Sharon D.  
LEGAL REPRESENTATIVE: Larson & Taylor  
NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 1131  
AB After a windowing operation  $h(n)$  performed by space-time weighting of the samples, a method and an apparatus for encoding-decoding a digital signal comprising a sequence of samples  $x(n)$  consists in performing a modified discrete cosine transform of the samples to calculate the even order transformation coefficients:  $\#EQU1\#\#$  for  $k \cdot \epsilon(0, \dots, N/2-1)$  with  $Y(k) = Y(k-1)$  The coefficient  $Y(2k)$   $\#EQU2\#\#$  for  $k=0, \dots, N/4-1$  with  $Y(n)=2n, h(2n) Y(n)$   
 $xN=cos(2 \cdot pi / 4N) \cdot h(N) \sin(2 \cdot pi / 4N)$  The invertible complex transformation is calculated using an auxiliary calculation equation:  $\#EQU3\#\#$  with:  $z(n)=(Y(2n)/N!-1/2n)+H(Y(N-1-2n)*Y(N/2-2n))$  The invention is applicable to encoding and decoding digital audio or video signals.

L25 ANSWER 46 OF 88 USPATFULL  
ACCESSION NUMBER: 94:93055 USPATFULL  
TITLE: Membrane expression of heterologous genes  
INVENTOR(S): Niesel, David W., League City, TX, United States  
Moncrief, J. Scott, Galveston, TX, United States  
Phillips, Linda H., Galveston, TX, United States  
Board of Regents, The University of Texas,  
Austin, TX, United States (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION: US 5347762 940920 APPLICATION INFO.: US 93-11759 930201 (8)	

PATENT INFORMATION: US 5356797 941018  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Schwartz, Richard A.  
ASSISTANT EXAMINER: Guzo, David  
LEGAL REPRESENTATIVE: Arnold, White & Durkee  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)  
LINE COUNT: 1390  
AB An apparatus and a method for processing lens peripheries which allow lenses to be properly fitted in a frame, i.e., which CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to nucleic acid segments useful in the construction of expression "vectors" for expression of heterologous polypeptides directed to particular areas of the host cell. Selected constructs direct production of polypeptides to the outer membrane surface of the cell. Other constructs direct expression of heterologous polypeptides to the inner membrane/plasmid of the host cell. Transformed host cells are potentially useful for the production of vaccines or immunogens elicited in response to antigens expressed on the outer membranes of the host cells.

L25 ANSWER 47 OF 88 USPATFULL  
ACCESSION NUMBER: 94:8934 USPATFULL  
TITLE:

Method and system for process expression and resolution including a generally and inherently concurrent computer language

INVENTOR(S): Fanti, Kan M., Minneapolis, MN, United States  
Brandt, Scott A., Minneapolis, MN, United States  
PATENT ASSIGNEE(S): Theuse Research, Inc., Minneapolis, MN, United States (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION: US 53555496 941011 DOCUMENT INFO.: US 92-837641 920214 (7) PRIMARY EXAMINER: Kulk, Paul V. LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Weiler & Schmidt NUMBER OF CLAIMS: 20 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 68 Drawing Figure(s); 27 Drawing Page(s) LINE COUNT: 5080	

AB A method and system for process expression and resolution is described. A first language structure comprising a possibility expression having at least one definition which is inherently and generally concurrent is provided. Further, a second language structure comprising an actually expression including a fully formed input data name to be resolved is provided. Furthermore, a third language structure comprising an active expression initially having at least one invocation, the invocation comprising an association with a particular definition and the fully formed input data name of the actuality expression is provided. Subsequently, the process of resolving invocations begins in the active expression with fully formed input data names in relation to their associated definition to produce at least one or both of the following: (1) an invocation with a fully formed input data name and (2) a result data name.

L25 ANSWER 48 OF 88 USPATFULL  
ACCESSION NUMBER: 94:89066 USPATFULL  
TITLE: Lens periphery processing apparatus, method for obtaining processing data, and lens periphery processing method  
INVENTOR(S): Shibata, Ryoji, Toyokawa, Japan  
Kobayashi, Masahiko, Aichi, Japan  
Ban, Yukinobu, Nishio, Japan  
Obayashi, Hirokatsu, Aichi, Japan  
PATENT ASSIGNEE(S): Nidek Co., Ltd., Gamagori, Japan (non-U.S. corporation)

NUMBER	DATE
PATENT INFORMATION: US 5347762 940920 APPLICATION INFO.: US 93-11759 930201 (8)	

PATENT INFORMATION: IP 92-54214 920204  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Rachuba, M.  
LEGAL REPRESENTATIVE: Nikaido, Marmelstein, Murray & Oram  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 6  
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 22 Drawing Page(s)  
LINE COUNT: 1150  
AB An apparatus and a method for processing lens peripheries which allow lenses to be properly fitted in a frame, i.e., which

processes lenses with high dimensional accuracy. For this purpose, the lens periphery processing apparatus and method are designed to comprise an input device for imputting the configuration of lens frame portions of the eyeglasses frame which is a result of three-dimensional measurement, a calculation device for deriving peripheral lengths of the lens frame portions from the three-dimensional lens frame portion configuration inputted by the input device, a tapered edge curve determining device for determining a curve value defined by the locus of the tapered edge of each lens, and a computing device for computing the locus of the tapered edge of each lens which substantially coincides with the peripheral length of the associated lens frame portion which is obtained by the calculation device.

L25 ANSWER 49 OF 88 USPATFULL  
ACCESSION NUMBER: 94:51887 USPATFULL  
TITLE: Measuring method and measuring apparatus  
INVENTOR(S): Matsunoto, Takahiro, Atsugi, Japan  
Yoshii, Minoru, Tokyo, Japan  
Saito, Kenji, Yokohama, Japan  
Nose, Hiroyasu, Zama, Japan  
Santoku, Koichi, Atsugi, Japan  
PATENT ASSIGNEE(S): Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER	DATE
PATENT INFORMATION: US 5321502 940614 APPLICATION INFO.: US 92-910457 920708 (7)	

PATENT INFORMATION: JP 91-171285 910711  
ACCESSION NUMBER: JP 92-16519 920131  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Wardan, Robert J.  
ASSISTANT EXAMINER: Carpenter, Robert  
LEGAL REPRESENTATIVE: Fitzpatrick, Celia, Harper & Scinto  
NUMBER OF CLAIMS: 9  
EXEMPLAR FIGURE(S): 1  
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 18 Drawing Page(s)  
LINE COUNT: 1786  
AB A measuring arrangement includes forming first and second pairs of light beams each having a low frequency light beam and a high frequency light beam. Both pairs of light beams generate beat signals of the same frequency. The low frequency light beam of either pair and the high frequency of the other pair pass through a predetermined optical path to cause phase changes in the same direction. Beat signals are generated by superimposing the first and second beam pair to provide measurement information on the phase changes.

L25 ANSWER 50 OF 88 USPATFULL  
ACCESSION NUMBER: 93-55484 USPATFULL  
TITLE: Process and device for real-time spectral analysis of complex unsteady signals  
INVENTOR(S): Demonten, Guy, Orsay, France  
Hermen, Alain, Paris, France  
Arcile, Claude, Igny, France  
Meutapa, Indira, Paris, France  
Houacine, Amara, Bab Ezzouar, Algeria  
Perronneau, Pierre, Paris, France  
PATENT ASSIGNEE(S): Institut National de la Santé et de la Recherche Médicale, France (non-U.S. government)

NUMBER	DATE
PATENT INFORMATION: US 5347762 940920 APPLICATION INFO.: US 93-11759 930201 (8)	

PRIORITY INFORMATION: FR 89-3761 890322

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Tokar, Michael J.

LEGAL REPRESENTATIVE: Larson and Taylor

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 397 Drawing Figure(s); 213 Drawing Page(s)

LINE COUNT: 10991

AB Two or more address spaces are provided in a data processor. One of the address spaces comprises control registers so that the control registers can be accessed using instructions having an address in the second address space. High-speed context switching can be accomplished by allotting the context-saving area to the second address space. The context can be saved in various formats specified by a context format register.

L25 ANSWER 51 OF 88 USPATFULL

ACCESSION NUMBER: 53-15237 USPATFULL

TITLE: Dynamic pattern matcher using incomplete data

INVENTOR(S): Wang, Lui, Houston, TX, United States

PATENT ASSIGNEE(S): Johnson, Gordon G., Princeton, NJ, United States

the United States National Aeronautics and Space Administration, Washington, DC, United States (U.S. government)

NUMBER DATE

PATENT INFORMATION: US 5189709 9302023

APPLICATION INFO.: US 91-749819 9110826 (7)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Couso, Jose L.

LEGAL REPRESENTATIVE: Bern, Hardie R.; Miller, Guy M.; Fair, Edward K.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 865

AB A method of matching a first query pattern with a plurality of stored data is disclosed. For each stored data pattern, the number of components are counted which are identical to corresponding components in the first query pattern, thereby forming a set of match numbers. If the number of components in any stored pattern, that stored data pattern is displayed as an output pattern set indicating a match. If no match exists then a second query pattern is determined by identifying the first query pattern, component by component, in dependence upon both a first, global influence of all stored patterns on all components of the first query pattern and a second, particular influence of all stored patterns on each respective component of the first query pattern. The first two method steps are then repeated using the second query pattern in place of the first query pattern. If no match a third query pattern similarity is determined by modifying the second query pattern. Finally, the output pattern is displayed, component by component, with those respective components of the third query pattern that have been modified at most once from the first query pattern.

L25 ANSWER 54 OF 88 USPATFULL

ACCESSION NUMBER: 93-7639 USPATFULL

TITLE: Exception, interrupt, and trap handling apparatus which fetches addressing and context data using a single instruction following an interrupt

INVENTOR(S): Sakamuro, Ken, Tokyo, Japan

PATENT ASSIGNEE(S): Mitsubishi Denki Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5182811 930126

APPLICATION INFO.: US 90-564945 900710 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 88-172035, filed on 23 Mar 1988, now abandoned

NUMBER DATE

PATENT INFORMATION: JP 87-247418 070930

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Lee, Thomas C.

ASSISTANT EXAMINER: Treat, William M.

LEGAL REPRESENTATIVE: Townsend and Townsend

NUMBER OF CLAIMS: 20

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 397 Drawing Figure(s); 213 Drawing Page(s)

LINE COUNT: 10251

AB A data processor executes the exception process, interrupt process and the trap instruction of internal interrupt instructions in a unified manner. The data processor is adapted to read an internal state variable simultaneously with reading the head address of an EIT process handler from an external memory when an EIT process is started so that it enables the internal state to be set on the basis of the information of the variable when the EIT process handler starts. The data processor is provided with multiple EIT process means which, when a plurality of EIT process requests are generated, decides the process order on the basis of priority from the content of the request. The data processor is also provided with means which specially treats the EIT process acceptance condition after returning from one EIT process handler, and thereby is generically free in programming.

L25 ANSWER 53 OF 88 USPATFULL

ACCESSION NUMBER: 53-15237 USPATFULL

TITLE: Receiver for a DS3 signal

INVENTOR(S): Neeser, Fredy D., Zurich, Switzerland

Huschmid, Markus D., Zurich, Switzerland

Ruprecht, Jurg P., Muri, Switzerland

Ascom Tech. AG., Bern, Switzerland (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5181225 930119

APPLICATION INFO.: US 91-79547 9711121 (7)

NUMBER DATE

PATENT INFORMATION: CH 90-3701 901122

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Barron, Jr., Gilberto

LEGAL REPRESENTATIVE: Brady, O'Boyle & Gates

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 2

NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)

AB In a receiver (3) for a DS3 signal (DSS3)-directed sequence spread spectrum, an inverse filter (12) is utilized in place of a matched filter for detecting the symbols (B, sub.m). The inverse filter (12) is distinguished in that it responds to the predetermined pulse sequence as such with a pure Kronecker delta sequence. Preferably, the DS3 signal is generated with a pulse sequence realizing a maximum process gain.

L25 ANSWER 56 OF 88 BIOSIS COPYRIGHT 1998 BIOSIS

ACCESSION NUMBER: 94-82397 BIOSIS

DOCUMENT NUMBER: 97095397

TITLE: Potato leafroll virus in solanaceous weeds in absence of known potato sources.

AUTHORS: Souza-Dias J A C D; Costa A S; Nardin A M

CORPORATE SOURCE: Instituto Agronomico Campinas, Caixa Postal 28,

13220-900-Campinas, SP, BRZ

SOURCE: Summa Phytopathologica 19 (2): 1953. 80-85. ISSN:

LANGUAGE: English

AB Outbreaks of potato leafroll virus (PLRV) in Brazil occur quite frequently in most of the main potato planting states. In the states of Sao Paulo and Parana, which hold the largest potato cultivated areas of the country, high grade seed potato lots, containing less than 1% of PLRV, may reach 20-80% of the virus in one or two multiplications only. Such a high inoculum pressure has been explained as due to outside inoculum sources, present among weeds and cultivated species other than potato. In this paper we report results from a survey conducted in the states of Sao Paulo and Parana in which natural infection of PLRV was demonstrated, by immuno (ELISA) and bio-assay, in 5 out of 8 solanaceous weeds sampled from the border or within potato plantations containing PLRV primarily infected plants. No known PLRV donor plants were present to be associated with such infection. Negative PLRV results were observed for samplings of the same species collected from non-potato planting

<p>information for a channel memory is controlled. Where unoccupied circuits are 2-up N (N: natural number) times the basic switching unit, incoming calls with a maximum of 2-sup N basic switching units in capacity may not be switched or transmitted by the unoccupied circuits depending on their status involving the presence of other calls. In that case, calls are relocated within a frame using the fewest steps possible. This is achieved by a neural network in the address control memory of multi-slot call switching system A. The neural network learning to output a call allocation pattern such that the number of times calls are relocated becomes minimal. The information from the network makes it possible to relocate the least number of times the calls whose capacity is not more than 2-sup N basic switching unit in the switching system A to another system B, connected oppositely to system A. Using the relocation information received, system B relocates calls within a channel memory of its own.</p>	<p><b>L25 ANSWER 59 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-38290 USPATFULL  <b>TITLE:</b> 11-2 analogs containing N-linked glycosylation sites</p> <p><b>PATENT ASSIGNEE(S):</b> Du Pont March Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5153310 921006</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 89-31717 890228 (7)</td> <td></td> </tr> <tr> <td><b>DOCUMENT TYPE:</b> Utility</td> <td></td> </tr> <tr> <td><b>PRIMARY EXAMINER:</b> Lacey, David L.</td> <td></td> </tr> <tr> <td><b>ASSISTANT EXAMINER:</b> Guest, Shelly J.</td> <td></td> </tr> <tr> <td><b>LEGAL REPRESENTATIVE:</b> Ferguson, Blair Q.; Karr, Don M.</td> <td></td> </tr> <tr> <td><b>NUMBER OF CLAIMS:</b> 12</td> <td></td> </tr> <tr> <td><b>EXEMPLARY CLAIM:</b> 1</td> <td></td> </tr> <tr> <td><b>LINE COUNT:</b> 660</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB Biologically active analogs of human IL2, which differ from natural IL2 by the substitution of amino acid residues to form N-linked glycosylation sites in the molecule, are prepared by recombinant DNA techniques. Such analogs of IL2 are N-linked glycosylated when expressed in eukaryotic cells. Natural IL2 is not N-linked glycosylated.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5153310 921006		<b>APPLICATION INFO.:</b> US 89-31717 890228 (7)		<b>DOCUMENT TYPE:</b> Utility		<b>PRIMARY EXAMINER:</b> Lacey, David L.		<b>ASSISTANT EXAMINER:</b> Guest, Shelly J.		<b>LEGAL REPRESENTATIVE:</b> Ferguson, Blair Q.; Karr, Don M.		<b>NUMBER OF CLAIMS:</b> 12		<b>EXEMPLARY CLAIM:</b> 1		<b>LINE COUNT:</b> 660		<p><b>L25 ANSWER 60 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-80754 USPATFULL  <b>TITLE:</b> Fermentation processes using amylolytic enzyme producing microorganisms</p> <p><b>PATENT ASSIGNEE(S):</b> Strasser, Alexander, Chopinstr 7, Dusseldorf, Germany, Federal Republic of</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5151354 920929</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 91-748161 910821 (7)</td> <td></td> </tr> <tr> <td><b>RELATED APPL. INFO.:</b> Division of Ser. No. US 87-85107, filed on 13 Aug 1987 which is a continuation-in-part of Ser. No. US 87-62943, filed on 16 Jun 1987, now abandoned</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The cloning of Schwannomyces glucamylase and alpha-amylase genes is taught. The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5151354 920929		<b>APPLICATION INFO.:</b> US 91-748161 910821 (7)		<b>RELATED APPL. INFO.:</b> Division of Ser. No. US 87-85107, filed on 13 Aug 1987 which is a continuation-in-part of Ser. No. US 87-62943, filed on 16 Jun 1987, now abandoned		<p><b>L25 ANSWER 62 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-18081 USPATFULL  <b>TITLE:</b> Adaptive control system for vehicles</p> <p><b>PATENT ASSIGNEE(S):</b> Takada, Masahiro, Hirakata, Japan</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5094127 920310</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 90-614514 901116 (7)</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5094127 920310		<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)	
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5153310 921006																																								
<b>APPLICATION INFO.:</b> US 89-31717 890228 (7)																																								
<b>DOCUMENT TYPE:</b> Utility																																								
<b>PRIMARY EXAMINER:</b> Lacey, David L.																																								
<b>ASSISTANT EXAMINER:</b> Guest, Shelly J.																																								
<b>LEGAL REPRESENTATIVE:</b> Ferguson, Blair Q.; Karr, Don M.																																								
<b>NUMBER OF CLAIMS:</b> 12																																								
<b>EXEMPLARY CLAIM:</b> 1																																								
<b>LINE COUNT:</b> 660																																								
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5151354 920929																																								
<b>APPLICATION INFO.:</b> US 91-748161 910821 (7)																																								
<b>RELATED APPL. INFO.:</b> Division of Ser. No. US 87-85107, filed on 13 Aug 1987 which is a continuation-in-part of Ser. No. US 87-62943, filed on 16 Jun 1987, now abandoned																																								
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5094127 920310																																								
<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																																								
<p><b>L25 ANSWER 63 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-18081 USPATFULL  <b>TITLE:</b> Adaptive control system for vehicles</p> <p><b>PATENT ASSIGNEE(S):</b> Takada, Kazushige, Neyagawa, Japan</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5094127 920310</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 90-614514 901116 (7)</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5094127 920310		<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)		<p><b>L25 ANSWER 64 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-18081 USPATFULL  <b>TITLE:</b> Adaptive control system for vehicles</p> <p><b>PATENT ASSIGNEE(S):</b> Ito, Osanu, Kodaira, Japan</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5094127 920310</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 90-614514 901116 (7)</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5094127 920310		<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)		<p><b>L25 ANSWER 65 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-18081 USPATFULL  <b>TITLE:</b> Adaptive control system for vehicles</p> <p><b>PATENT ASSIGNEE(S):</b> Matsushita Electric Industrial Co., Ltd., Osaka, Japan (non-U.S. corporation)</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5094127 920310</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 90-614514 901116 (7)</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5094127 920310		<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																		
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5094127 920310																																								
<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																																								
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5094127 920310																																								
<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																																								
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5094127 920310																																								
<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																																								
<p><b>L25 ANSWER 66 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-18081 USPATFULL  <b>TITLE:</b> Adaptive control system for vehicles</p> <p><b>PATENT ASSIGNEE(S):</b> Matsushita Electric Industrial Co., Ltd., Osaka, Japan (non-U.S. corporation)</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5094127 920310</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 90-614514 901116 (7)</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5094127 920310		<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)		<p><b>L25 ANSWER 67 OF 88 USPATFULL</b>  <b>ACCESSION NUMBER:</b> 92-18081 USPATFULL  <b>TITLE:</b> Adaptive control system for vehicles</p> <p><b>PATENT ASSIGNEE(S):</b> Matsushita Electric Industrial Co., Ltd., Osaka, Japan (non-U.S. corporation)</p>	<table border="1"> <thead> <tr> <th>NUMBER</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td><b>PATENT INFORMATION:</b> US 5094127 920310</td> <td></td> </tr> <tr> <td><b>APPLICATION INFO.:</b> US 90-614514 901116 (7)</td> <td></td> </tr> </tbody> </table> <p><b>CAS INDEXING IS AVAILABLE FOR THIS PATENT.</b></p> <p>AB The genes are expressed in recombinant host cells.</p>	NUMBER	DATE	<b>PATENT INFORMATION:</b> US 5094127 920310		<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																										
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5094127 920310																																								
<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																																								
NUMBER	DATE																																							
<b>PATENT INFORMATION:</b> US 5094127 920310																																								
<b>APPLICATION INFO.:</b> US 90-614514 901116 (7)																																								

**EXEMPLARY CLAIM:** 1  
**NUMBER OF DRAWINGS:** 11 Drawing Figure(s); 10 Drawing Page(s)  
**LINE COUNT:** 626  
**AB** An adaptive control system for vehicles using a time delay control method which applies a reference model for giving desired response characteristics, assumes that terms of an unknown section such as for variations of plant dynamics are constant for a minute time period, and estimates this variation of the unknown section to calculate a control input that follows said reference model.

L25 ANSWER 63 OF 88 USPAFULL

ACCESSION NUMBER: 91:24767 USPAFULL

TITLE: DNA coding for antigen protein of rinderpest virus

INVENTOR(S): Yamanouchi, Kazuya, Fuchi, Japan

Yoshikawa, Yoshihiro, Hoya, Japan

Sugimoto, Masanobu, Shiki, Japan

PATENT ASSIGNEE(S): Toa Nenryo Kogyo Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5003058 910326  
APPLICATION INFO.: US 87-30550 870628 (7)

NUMBER DATE

PRIORITY INFORMATION: JP 86-201765 880829  
JP 87-70413 870326

DOCUMENT TYPE: Utility

ASSISTANT EXAMINER: Mosher, M.

LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 11 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

**AB** A DNA coding for an entire or a part of an antigen protein of the rinderpest virus, a protein for the production of the DNA comprising the steps of preparing an mRNA from the rinderpest virus, preparing a cDNA library from the mRNA, selecting a cDNA coding for the target protein from the cDNA library, and cloning the selected cDNA in a cloning "vector"; and a protein for the production of the antigen protein of the rinderpest virus comprising the steps of transferring a "vector" containing the DNA coding for the target protein into animal cells, culturing the animal cells to produce the antigen protein, and recovering the target protein from the cell culture.

L25 ANSWER 64 OF 88 USPAFULL

ACCESSION NUMBER: 90:37062 USPAFULL

TITLE: Magnetic field screens

INVENTOR(S): Mansfield, Peter, Nottingham, England

Chapman, Barry L. W., Nottingham, England

Turner, Robert, Nottingham, England

Bowley, Roger M., Nottingham, England  
PATENT ASSIGNEE(S): National Research Development Corporation, London, England (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4978920 901218

APPLICATION INFO.: US 89-338352 890414 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 86-309292, filed on 19 Sep 1986, now abandoned

NUMBER DATE

PRIORITY INFORMATION: GB 85-23326 850920

GB 86-2811 850206

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Tokar, Michael J.

LEGAL REPRESENTATIVE: Cushman, Darby & Cushman

NUMBER OF CLAIMS: 37  
EXEMPLARY CLAIM: 1

**NUMBER OF DRAWINGS:** 40 Drawing Figure(s); 13 Drawing Page(s)  
**LINE COUNT:** 1056  
**AB** The screen is provided by surrounding the coil producing the magnetic field with a set of electrical conductors the currents within the conductors being controlled in such a manner that the field is neutralized in a specific region of space, the current distribution within the conductors being determined by calculating the current within a hypothetical superconductive shield which would have the effect of neutralizing the field, the current through the conductors thereby being a substitute for the superconductive shield.

L25 ANSWER 65 OF 88 USPAFULL

ACCESSION NUMBER: 90:66124 USPAFULL

TITLE: Direct digital synthesizer with selectively randomized accumulator

INVENTOR(S): Essentwanger, Kenneth A., Walnut, CA, United States  
PATENT ASSIGNEE(S): Hughes Aircraft Company, Los Angeles, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4951237 900821

APPLICATION INFO.: US 88-184642 8804022 (7)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Maizahn, David H.

LEGAL REPRESENTATIVE: Denson-Low, Wanda K.

EXEMPLARY CLAIM: 21

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)

LINE COUNT: 647

**AB** A direct digital synthesizer (DDS) accumulator circuit is disclosed wherein a selected few of the low order accumulator bits are dithered by a pseudorandom number generator in order to introduce a frequency deviation density to suppress spurious signals including those close-in to the output or fundamental frequency. The accumulator circuit may advantageously be sectioned into a lower order accumulator and higher order accumulator in a pipelined combination with a sine approximation output circuit in order to construct a DDS circuit wherein such spur suppression is achieved without decreasing system throughput.

L25 ANSWER 66 OF 88 USPAFULL

ACCESSION NUMBER: 90:8151 USPAFULL

TITLE: Key management system for open communication environments

INVENTOR(S): Pollard, Alan J., Winnipeg, Canada  
Lemire, James R., Winnipeg, Canada  
PATENT ASSIGNEE(S): The Manitoba Telephone System, Winnipeg, Canada

NUMBER DATE

PATENT INFORMATION: US 4897875 900130

APPLICATION INFO.: US 87-32625 870503 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 85-710429, filed on 11 Mar 1985, now abandoned

NUMBER DATE

PRIORITY INFORMATION: GB 86-21333 860904

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Buczinski, Stephen C.

ASSISTANT EXAMINER: Gregory, Bernar Earl

LEGAL REPRESENTATIVE: Battison, Adrian D.; Ade, Stanley G.; Thrift, Murray E.

NUMBER CLAIMS: 22

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 1354

**AB** A telecommunications security device for use on the communication medium includes a first and a second security unit each arranged to be inserted into for example the telephone line adjacent a user device. The units are identical and therefore either can act as a central unit for example for a computer access port with the other

providing one of a set of remote units. Each unit includes a separable memory module with all the modules having a memory storing identical information. The information stored includes a plurality of pairs of random signals one of each pair providing a request signal and the other the security code. The central unit on receipt of a telephone call provides a signal requesting an ID code from the remote unit and on receipt of the ID code issues one from the two pairs the security code request signal. On matching the received code with the expected code a transmission gate is opened. The pairs used in turn until all of the pairs have been used whereupon an indicator shows this condition. The modules can be removed and the memory re-written with fresh pairs of codes. The key includes a security logic circuit which controls access to the numbers to a fixed set of access rules allowing unauthorized access.

L25 ANSWER 67 OF 88 USPAFULL

ACCESSION NUMBER: 88-49870 USPAFULL

TITLE: Position control system including a quick response control

INVENTOR(S): Itoh, Hinachi, Numazu, Japan  
PATENT ASSIGNEE(S): Toshiba Kikai Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4841208 890620

APPLICATION INFO.: US 87-95110 870911 (7)

NUMBER DATE

PATENT INFORMATION: JP 86-214741 860911

JP 87-86649 870407

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ro, Benito

LEGAL REPRESENTATIVE: Birch, Stewart, Kalasch & Birch

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)

LINE COUNT: 534

**AB** A position control system comprises a position command generator for generating a position command at a prescribed sampling time  $k$  for a time  $K+k$  which is at least one sampling cycle  $M$  ahead of the prescribed sampling time. A controlled object includes a speed control loop, and a control unit for generating a control input value determined by determining a weight coefficient of each of position commands at sampling times  $k+1, 2, \dots, M$  and a weight coefficient for the position and speed which are outputs of the controlled object in order to minimize the value of an evaluation function so that the position command at the prescribed sampling time  $k$  and the position of the controlled object will be equalized, while the position commands produced by the position command generator at the sampling times  $k+1, 2, \dots, M$ , the position and speed of the controlled object, and a control input to be applied to the controlled object are being used as variables.

L25 ANSWER 68 OF 88 USPAFULL

ACCESSION NUMBER: 88-47604 USPAFULL

TITLE: Target tracking system

INVENTOR(S): Piccoluz, Heinz, Regensdorf, Switzerland  
PATENT ASSIGNEE(S): Contraves AG, Zurich, Switzerland (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4760397 860736

APPLICATION INFO.: US 87-134751 871218 (7)

NUMBER DATE

PATENT INFORMATION: CH 86-5216 861222

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Tübbersing, T. H.

ASSISTANT EXAMINER: Barron, Jr., Gilberto

LEGAL REPRESENTATIVE: Kleeman, Werner W.

NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 1657

AB The target tracking system has high tracking reliability at small servo load and comprises a plural number of groups of target sensors having tracking signal travelling times which vary from one group to the other and defining respective lines of sight; a servo system causing the lines of sight to track the target; a target estimator for estimating the movement of the target; a servo estimator for estimating the movement of the servo system; and a regulator which identically controls the servo system and the servo estimator such that the vectorial difference between the estimate of the target movement and the estimate of the servo movement is caused to approach zero. During the target tracking operation, vectorial target deviation signals which are generated by groups of angle sensors, are processed by multipliers using respective matrices in order to produce rated combined target deviation signals. The thus processed vectorial target deviation signals are directly applied to the servo system and the servo estimator in a manner as if there would be present only one respective angle sensor producing the combined target deviation signal.

L25 ANSWER 69 OF 88 USPATFULL  
ACCESSION NUMBER: 88-39471 USPATFULL

TITLE: Precision platform pointing controller for a dual-spin spacecraft  
INVENTOR(S): Stafer, Loren I., Los Angeles, CA, United States  
Blender, Douglas J., Santa Barbara, CA, United States  
Yocom, John F., Rancho Palos Verdes, CA, United States

PATENT ASSIGNEE(S): Hughes Aircraft Company, Los Angeles, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4752884 880821  
APPLICATION INFO.: US 85-756387 850718 (6)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Chin, Gary  
LEGAL REPRESENTATIVE: Mitchell, S. M.; Meltzer, M. J.; Karambelas, A. W.

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 27 Drawing Page(s)  
LINE COUNT: 1753

AB A pointing apparatus for a dual-spin spacecraft utilizing a first sensor for sensing the time of arrival of an inertial attitude reference as the spinning portion of the spacecraft rotates, and a second sensor for sensing the time of arrival of an index reference which relates the position of the despun portion with the spinning portion. A digital processor estimates the spin rate and phase of the spinning portion from the inertial attitude reference line of arrival, estimates the relative spin rate and phase between the spinning portion and the despun portion from the index bias torque on the motor means which controls the pointing direction of the despun portion of the spacecraft. The relative spin rate and phase estimates are added with the despun portion spin rate and phase, to produce an estimate of the despun portion spin rate and phase, and the despun portion spin rates and phase estimates and the friction bias torque estimates are subtracted from commanded despun portion spin rate, phase and friction bias torque states. A torque command is generated for controlling the motor means from the subtracted estimates.

L25 ANSWER 70 OF 88 USPATFULL  
ACCESSION NUMBER: 88-34433 USPATFULL  
TITLE: Process for recovering refractile bodies containing heterologous proteins from microbial hosts  
INVENTOR(S): Dorin, Glenn, San Rafael, CA, United States  
Hanisch, Wolfgang H., Baltimore Heights, Austria  
Lin, Leo S., Walnut Creek, CA, United States

PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4748234 880531  
APPLICATION INFO.: US 86-843987 860325 (6)  
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 85-749551, filed on 26 Jun 1985, now abandoned  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Kight, John  
ASSISTANT EXAMINER: Draper, Garnette D.  
LEGAL REPRESENTATIVE: Halluin, Alain P.; Lauder, Leona L.; McLaughlin, Jane R.

NUMBER OF CLAIMS: 46

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 1695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A refractive material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves disrupting the cell wall and membrane of the host cell, removing greater than 99% by weight of the salts from the disruptate, disrupting the refractive material, adding a material to the disruptate to create a density or viscosity gradient in the liquid within the disruptate, and separating the refractive material from the cellular debris by high-speed centrifugation. Another version of such a recovery process comprises the further steps of solubilizing the refractive material under reducing conditions, organically extracting the solubilized refractive material, and isolating said refractive material from the extractant.

Preferably the protein is recombinant IL-2 or IFN- $\beta$ , and the salt removal step is carried out by diafiltration.

L25 ANSWER 71 OF 88 USPATFULL  
ACCESSION NUMBER: 88-31125 USPATFULL

TITLE: <sup>sup.59</sup> Valine insulin-like growth factor 1 and process for production thereof  
INVENTOR(S): Ueda, Ikuo, Toyonaka, Japan  
Niwa, Mineo, Mukoo, Japan  
Saito, Yoshimasa, Osaka, Japan  
Sato, Susumu, Osaka, Japan  
Oho, Hiroki, Osaka, Japan  
Kitaguchi, Tadashi, Amegasaki, Japan  
Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan  
(non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4745179 880517  
APPLICATION INFO.: US 85-713828 850320 (6)

NUMBER DATE

PRIORITY INFORMATION: GB 84-8473 840402  
GB 84-13989 840601  
GB 84-24157 840925

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kight, John

ASSISTANT EXAMINER: Chan, Christina

LEGAL REPRESENTATIVE: Olion, Fisher, Spivak, McClelland & Maier

NUMBER OF CLAIMS: 3

EXEMPLARY CLAIM: 1

LINE COUNT: 1480

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a sup 59 Valine insulin-like growth factor 1 (sup 59 Val-IGF-1), to a sup 59 Val-IGF-1 fused to a protective peptide, to a gene coding for sup 59 Val-IGF-1, to a gene coding for fused sup 59 Val-IGF-1, to a plasmid containing the sup 59 Val-IGF-1 gene, to a host organism containing a plasmid containing the sup 59 Val-IGF-1 gene, to a host organism containing a plasmid containing the fused sup 59 Val-IGF-1 gene, and to processes for the production of these.

ACCESSION NUMBER: 88-17913 USPATFULL  
TITLE: Active site modified protease

INVENTOR(S): Bar, Philip J.; Ohinda, CA, United States  
Halewell, Robert A., San Francisco, CA, United States

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4732973 880322  
APPLICATION INFO.: US 84-620408 840614 (6)  
DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Phillips, Delbert R.

LEGAL REPRESENTATIVE: Ciotti & Murashige, Irrell & Manella

NUMBER OF CLAIMS: 4

EXEMPLARY CLAIM: 1

LINE COUNT: 631

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Proteinaceous composition are provided which inhibit naturally occurring serine proteases. Particularly, an amino acid sequence analogous to human  $\alpha$ -chymotrypsin is modified at the active site while maintaining protease inhibition. The methionine at the active site is substituted with an oxidatively stable amino acid, while other amino acids may also be changed, added or deleted, particularly at the termini.

The yeast strains AB103.1 (pcDNA1(Pho5AT)Val) and AB110 (pcDNA1(GaPAP1)Val) were deposited at the A.T.C.C. on June 18, 1984 and given Accession Nos. 20711 and 20712, respectively.

L25 ANSWER 73 OF 88 MEDLINE  
ACCESSION NUMBER: 88149037 MEDLINE

TITLE: Transformation of Clostridium perfringens L forms with shuttle plasmid DNA.

AUTHOR: Mahony D. E.; Mader J. A.; Dubel J. R.

CORPORATE SOURCE: Department of Microbiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

SOURCE: APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (1988 Jan) 54 (1) 264-7.

JOURNAL CODE: 5K8, ISSN: 0099-2240.

PUB. COUNTRY: United States

JOURNAL: Article, (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198808

AB L-form (L-phase) cultures of Clostridium perfringens were tested for their transformability with plasmid DNA. Three L-form strains were transformable, but one, strain <sup>\*\*\*L\*\*\*</sup> - <sup>\*\*\*13\*\*\*</sup>, was superior to the others. This strain was easily and reproducibly transformed with previously described shuttle <sup>\*\*\*Yac1\*\*\*</sup> vectors which were derived from either C. perfringens or Escherichia coli. Strain <sup>\*\*\*L\*\*\*</sup> - <sup>\*\*\*13\*\*\*</sup> was transformable by a variety of methods, and a new micromethod worked well under both aerobic and anaerobic conditions. The maximal number of transformants was attained after strain <sup>\*\*\*L\*\*\*</sup> - <sup>\*\*\*13\*\*\*</sup> was exposed for 4 h to the transforming DNA and polyethylene glycol. Viable counts determined in tubes of semisolid brain heart infusion medium containing 10% sucrose, with or without 2 micrograms of tetracycline per ml, showed a transformation rate of 3.9 X 10<sup>(-5)</sup> (transformants per viable cells).

L25 ANSWER 74 OF 88 USPATFULL  
ACCESSION NUMBER: 87-47495 USPATFULL

TITLE: Process and system for programming robot movements

INVENTOR(S): Arbeiter, Klaus, Moorenweis, Germany, Federal Republic of

PATENT ASSIGNEE(S): Deutsche Forschungs- und Versuchsanstalt für Luft- und Raumfahrt e.V., Cologne, Germany, Federal Republic of (non-U.S. corporation)

NUMBER DATE

L25 ANSWER 72 OF 88 USPATFULL

PATENT INFORMATION: US 4677568 870330  
APPLICATION INFO.: US 85-731831 850508 (6)

NUMBER DATE

PRIORITY INFORMATION: DE 84-34178884 0514  
DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ruggiero, Joseph  
LEGAL REPRESENTATIVE: Collard, Roe & Galgano

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)  
LINE COUNT: 386

AB There is provided a process and system for the memory-saving programming of the motional actions of a robot wherein a reference course is recorded first in the form of samples, which are then stored. For reducing the storage space, the recorded and stored samples are transformed into a Fourier matrix, sub. 0 C by means of a Fourier analysis. Said matrix is then filed in a memory. From this Fourier matrix, sub. 0 C, it is possible to derive a Fourier matrices for courses with the same configuration, but with any desired position and orientation solely by a linear transformation of the coordinates in the form of a Fourier matrix, sub. 1 C. With the help of the dynamical model of the robot used, the derived Fourier matrix, sub. 1 C can be modified with adjustment to the desired speed, so as to compensate for the dynamical errors in the motional actions of the robot. For creating the course coordinates which the robot can then follow when performing its movements, the modified Fourier matrix C is subjected to a final Fourier synthesis with predetermination of an arc length (s) conforming to the desired course speed (v). In this way, not only is memory-saving programming achieved, but the dynamics of the robot can be compensated for within the spectral range irrespective of speed if the dynamics of the robot used can be represented by a transmission function.

L25 ANSWER 75 OF 88 USPAFULL

ACCESSION NUMBER: 87-24817 USPAFULL  
TITLE: Superconducting filer coils for high homogeneity

INVENTOR(S): Keim, Thomas A., Clifton Park, NY, United States  
Mayorgoz, Isaak D., Rockville, MD, United States

PATENT ASSIGNEE(S): General Electric Company, Schenectady, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4656447 870407  
APPLICATION INFO.: US 84-625076 840627 (6)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Harns, George  
LEGAL REPRESENTATIVE: Cutler, Lawrence D.; Davis, James C.; Snyder, Marvin

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 2 Drawing Page(s)  
LINE COUNT: 725

AB When a closed circuit is formed by joining superconducting wires with superconducting joints, the current in that circuit adjusts itself as required to maintain whatever total flux linkage the circuit had at the instant superconductivity was achieved. In particular, a closed circuit which first becomes superconducting under conditions of zero net flux linkage maintains zero net flux linkage as long as the circuit remains superconducting. By appropriately configuring a set of short-circuited superconducting coils, a field inside a volume described by the coils is kept substantially more uniform than it would be if the same volume were magnetized by the same source in the absence of the short-circuited coils. This property is used to insure that the volume within the coils exhibits improved magnetic field homogeneity.

L25 ANSWER 76 OF 88 MEDLINE  
ACCESSION NUMBER: 88126759 MEDLINE  
DOCUMENT NUMBER: 88126759  
TITLE: Infection rates and parasitic loads of Onchocerca

vulvulus, and other filariae, in Simulium sanctipauli s.l. and S. yahense in a rain-forest area of Liberia.

AUTHOR: Garris R  
CORPORATE SOURCE: Bernhard-Nocht-Institut fur Schiffs- und Tropenkrankheiten, Hamburg, Department of Entomology..

SOURCE: TROPICAL MEDICINE AND PARASITOLOGY, (1987 Sep) 38 (3)

ENTRY MONTH: 2014.

JOURNAL CODE: TRP ISSN: 0177-2382.  
COUNTRY: GERMANY, WEST; Germany, Federal Republic of  
JOURNAL ARTICLE: (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198805

AB Simulium sanctipauli s.l. and S. yahense are common and widespread in the rain-forest zone of Liberia, but differ with regard to their biting densities and contribution to the transmission of Onchocerca sanctipauli s.l. (presumably S. sanctipauli in the sense of Pcs) was the predominant ma-biting species (74.3% of 30,855 females examined). S. yahense was shown to be the important "vector"\*\*\*. While 1000 biting females of S. yahense carried 96 3rd stage larvae indistinguishable from O. volvulus, only 14 were found per 1000 females of S. sanctipauli s.l. Of the parasitic females (3135 S. sanctipauli s.l./1623 S. yahense) 23.8639% harboured 1st instar 2nd stage filarial larvae and 1.979.4% 3rd stage larvae of O. volvulus. Animal filariae of unknown origin, indicative of zoophily, were very common in S. sanctipauli s.l. \*\*\* ( \*\*\*+13\*\*\* .8%) but practically absent from S. yahense (0.5%). In spite of its poorer vectorial performance S. sanctipauli s.l. cannot be neglected as a "vector"\*\*\* because it may occur in high biting densities and contribute considerably to the transmission, in particular in the vicinity of the St. Paul River. The interplay of two \*\*\*vector\*\*\* species, which develop in different types of water-courses explains the overall high endemicity of onchocerciasis in the study area.

L25 ANSWER 76 OF 88 USPAFULL

ACCESSION NUMBER: 86-63810 USPAFULL

TITLE: Circuitry for generating scalar products and sums of floating point numbers with maximum accuracy

INVENTOR(S): Kuisch, Ulrich, Im Eichbaumle 37, 7500 Karlsruhe, Germany, Federal Republic of

NUMBER DATE

PATENT INFORMATION: US 4622850 861111  
APPLICATION INFO.: US 85-64517 850809 (6)

RELATED APPN. INFO.: Continuation of Ser. No. US 82-438561, filed on 2 Nov 1982, now abandoned

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)  
LINE COUNT: 1362

AB Circuitry for generating scalar products and sums of floating point numbers with maximum accuracy and circuitry and a method for electronic computers by which scalar products of floating point numbers of the type pi. q, Esb1,e1,e2 are summed with full precision in a fixed point representation by means of a summing unit (ALU) and one or more accumulator registers (ARC1, ARC2) with cells (A1,1) for storing of codes of a base b having a length (2l+2, 6l+2e2) for fixed point representation and certain overflow positions. By control means (SHR, E, Cont) the mantissas of products are delivered depending on the value of the respective exponents into the summing unit (ALU). By control means (RD, Contro), rounding operations (circle, gradient, increment,) demanded by the higher level computer are performed, and a rounded floating point number (quadrature, c epsilon).

L25 ANSWER 78 OF 88 USPAFULL  
ACCESSION NUMBER: 86157264 USPAFULL  
TITLE: Coil construction for electromagnetic treatment of an afflicted body region

INVENTOR(S): Moore, John S., Upper Montclair, NJ, United States

PATENT ASSIGNEE(S): Electro-Biology, Inc., Fairfield, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: DE 81-3144015811105

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Thomas, James D.

ASSISTANT EXAMINER: Shaw, Dale M.

LEGAL REPRESENTATIVE: Sprung Horn Kramer & Woods

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)  
LINE COUNT: 1362

AB

When a closed circuit is formed by joining superconducting wires with superconducting joints, the current in that circuit adjusts itself as required to maintain whatever total flux linkage the circuit had at the instant superconductivity was achieved. In

particular, a closed circuit which first becomes superconducting under conditions of zero net flux linkage maintains zero net flux linkage as long as the circuit remains superconducting. By appropriately configuring a set of short-circuited superconducting coils, a field inside a volume described by the coils is kept substantially more uniform than it would be if the same volume were magnetized by the same source in the absence of the short-circuited coils. This property is used to insure that the volume within the coils exhibits improved magnetic field homogeneity.

NUMBER	DATE	PATENT INFORMATION	NUMBER	DATE	PATENT INFORMATION	NUMBER	DATE
PATENT INFORMATION:	US 4570217 860211	APPLICATION NUMBER: US 4570217 860211	NUMBER	DATE	PATENT INFORMATION: US 4093941 780606	NUMBER	DATE
APPLICATION INFO.:	US 83-479191 830328 (6)	RELATED APPN. INFO.: Continuation-in-part of Ser. No. US 82-363404, filed on 29 Mar 1982, now abandoned	APPLICATION INFO.:	US 76-49200 761209 (5)	APPLICATION INFO.:	US 4093941 780606	APPLICATION INFO.:
DOCUMENT TYPE:	Utility	PRIMARY EXAMINER: Ruggiero, Joseph	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:
PRIMARY EXAMINER:	Ruggiero, Joseph	LANGUAGE: English	PRIMARY EXAMINER:	Bourreau, Leo H.	PRIMARY EXAMINER:	Vandigriff, John E.	PRIMARY EXAMINER:
LEGAL REPRESENTATIVE:	Ware, Robert H.; Stoltz, Melvin I.; Fressola, Alfred A.	SOURCE: MOL GEN GENET 198 (2): 1985. 279-282. CODEN: MGGEA; ISSN: 0026-8925	NUMBER OF CLAIMS: 43	EXEMPLARY CLAIM: 1	NUMBER OF CLAIMS: 14	EXEMPLARY CLAIM: 1	NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM:	AB. The genes for the ribosomal proteins S9 (rps) and L13 (rpl) of E. coli were cloned into a lambda phage vector termed L47.1. The 2 genes were identified by infecting UV-light irradiated cells with the resultant phages and analyzing the protein products by 2-dimensional gel electrophoresis. Suitable DNA fragments of their nucleotide sequence was determined by the dideoxy method. The 2 genes form a transcription unit, the rplM gene being promoter-proximal. There is a typical signal sequence for transcriptional termination after the rpsL gene. The codon usage pattern in the 2 genes is similar to other ribosomal protein genes of E. coli.	NUMBER OF DRAWINGS: 119 Drawing Figure(s); 105 Drawing Page(s)	LINE COUNT: 5396	LINE COUNT: 1	NUMBER OF DRAWINGS: 120 Drawing Figure(s); 45 Drawing Page(s)	LINE COUNT: 5396	NUMBER OF DRAWINGS: 120 Drawing Figure(s); 45 Drawing Page(s)
LINE COUNT:	17226	AB. A man-machine interface for use with industrial processes is disclosed having the capability of design and configuration or the interrelationship of components forming an overall industrial process. The man-machine interface further provides operator use, including process monitoring and control, as well as alarm annunciation. Most user interaction with the man-machine interface is performed through a color CRT monitor having a touch panel on the surface of the CRT screen. Operator use may be limited to touch panel interaction while configurer and designer use normally further includes use of a keyboard.	NUMBER OF DRAWINGS: 119 Drawing Figure(s); 105 Drawing Page(s)	LINE COUNT: 5396	NUMBER OF DRAWINGS: 120 Drawing Figure(s); 45 Drawing Page(s)	LINE COUNT: 5396	NUMBER OF DRAWINGS: 120 Drawing Figure(s); 45 Drawing Page(s)
L25 ANSWER 82 OF 88 USPATFULL	ACCESSION NUMBER: 79-32459 USPATFULL	INVENTOR(S): Waiden, Jack M., Loveland, CO, United States	NUMBER	DATE	PATENT INFORMATION: US 4180854 791225	NUMBER	DATE
ACCESSION NUMBER:	79-32459 USPATFULL	Eads, William D., Loveland, CO, United States	APPLICATION INFO.:	US 77-83771 770929 (5)	APPLICATION INFO.:	US 4068298 780110	APPLICATION INFO.:
TITLE:	Programmable calculator having string variable editing capability	Cozzens, Ray J., Loveland, CO, United States	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:
INVENTOR(S):	Waiden, Jack M., Loveland, CO, United States	Bindwill, John L., Loveland, CO, United States	PRIMARY EXAMINER:	Zach, Edward Lewis, Cleveland Heights, OH, United States	PRIMARY EXAMINER:	Zach, Edward Lewis, Cleveland Heights, OH, United States	PRIMARY EXAMINER:
NUMBER OF CLAIMS:	35	Wilson, Martin S., Loveland, CO, United States	LEGAL REPRESENTATIVE:	Pitt, Paul Eldred, Malibu, CA, United States	LEGAL REPRESENTATIVE:	Glaser, Edward Lewis, Cleveland Heights, OH, United States	LEGAL REPRESENTATIVE:
EXEMPLARY CLAIM:	AB. A man-machine interface for use with industrial processes is disclosed having the capability of design and configuration or the interrelationship of components forming an overall industrial process. The man-machine interface further provides operator use, including process monitoring and control, as well as alarm annunciation. Most user interaction with the man-machine interface is performed through a color CRT monitor having a touch panel on the surface of the CRT screen. Operator use may be limited to touch panel interaction while configurer and designer use normally further includes use of a keyboard.	Jawett, Robert A., Loveland, CO, United States	NUMBER OF CLAIMS: 2	EXEMPLARY CLAIM: 1	NUMBER OF DRAWINGS: 470 Drawing Figure(s); 454 Drawing Page(s)	LINE COUNT: 12183	NUMBER OF DRAWINGS: 470 Drawing Figure(s); 454 Drawing Page(s)
The man-machine interface utilizes distributed processing and incorporates a high level graphic language. The graphic language facilitates real time graphic display implementation through use of dynamic and static variables. Variable types are dynamically associated with variable values so that variables can undergo type changes without detrimental effect. Video bit bangers and shifters further enhance the versatility and ease of implementing rapid modifications of graphic displays. The man-machine interface further incorporates a new bus structure including a new bus arbitration technique, a unidirectional memory boundary protection mechanism, an improved interrupt system, and an improved watchdog timer circuit.	Grimm, Daniel J., Loveland, CO, United States	NUMBER OF CLAIMS: 1	EXEMPLARY CLAIM: 1	NUMBER OF DRAWINGS: 470 Drawing Figure(s); 454 Drawing Page(s)	LINE COUNT: 12183	NUMBER OF DRAWINGS: 470 Drawing Figure(s); 454 Drawing Page(s)	LINE COUNT: 12183
L25 ANSWER 80 OF 88 USPATFULL	ACCESSION NUMBER: 85-39807 USPATFULL	INVENTOR(S): Alba, Emilio G., Conrado de Trevino 12, Madrid, Spain	NUMBER	DATE	PATENT INFORMATION: ES 79-482374 790710	NUMBER	DATE
ACCESSION NUMBER:	85-39807 USPATFULL	Pacho, Angel R., Paseo de la Habana 40, Madrid, Spain	APPLICATION INFO.:	US 80-161448 800620 (6)	APPLICATION INFO.:	US 75-637511 751203 (5)	APPLICATION INFO.:
TITLE:	Voltage stabilizing transformer	NUMBER OF CLAIMS: 6	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:
INVENTOR(S):	Alba, Emilio G., Conrado de Trevino 12, Madrid, Spain	PRIMARY EXAMINER: Beha, Jr., William H.	LEGAL REPRESENTATIVE: Penrice & Edmonds	NUMBER OF CLAIMS: 6	EXEMPLARY CLAIM: 1	NUMBER OF CLAIMS: 393	EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 8 Drawing Page(s)	NUMBER OF CLAIMS: 1	EXEMPLARY CLAIM: 1	NUMBER OF DRAWINGS: 160 Drawing Figure(s); 144 Drawing Page(s)	LINE COUNT: 28817	NUMBER OF DRAWINGS: 160 Drawing Figure(s); 144 Drawing Page(s)	LINE COUNT: 28817
LINE COUNT:	367	NUMBER OF CLAIMS: 6	EXEMPLARY CLAIM: 1	NUMBER OF DRAWINGS: 160 Drawing Figure(s); 144 Drawing Page(s)	AB. Data processing information storage and retrieval system having a memory. A number of modules are interconnected with the memory. Encode and decode modules operate in conjunction with the memory for compacting and expanding data. A ravive module in association with a delta module and a memory enable data signals to be transferred into a number of unique but equivalent read signals to be received by a seed module. A seed module enables the shortest of the equivalent signals to be updated. An output module causes an equivalent signal to be converted back to the original signal representation. Pipe and brightness modules perform a discrimination function on stored information. The data processor includes programs which by unique means and methods structure and retrieve data from the data base. The retrieval may be based on an index match between events and entries on a request and the structured data base.	AB. Data processing information storage and retrieval system having a memory. A number of modules are interconnected with the memory. Encode and decode modules operate in conjunction with the memory for compacting and expanding data. A ravive module in association with a delta module and a memory enable data signals to be transferred into a number of unique but equivalent read signals to be received by a seed module. A seed module enables the shortest of the equivalent signals to be updated. An output module causes an equivalent signal to be converted back to the original signal representation. Pipe and brightness modules perform a discrimination function on stored information. The data processor includes programs which by unique means and methods structure and retrieve data from the data base. The retrieval may be based on an index match between events and entries on a request and the structured data base.	AB. Data processing information storage and retrieval system having a memory. A number of modules are interconnected with the memory. Encode and decode modules operate in conjunction with the memory for compacting and expanding data. A ravive module in association with a delta module and a memory enable data signals to be transferred into a number of unique but equivalent read signals to be received by a seed module. A seed module enables the shortest of the equivalent signals to be updated. An output module causes an equivalent signal to be converted back to the original signal representation. Pipe and brightness modules perform a discrimination function on stored information. The data processor includes programs which by unique means and methods structure and retrieve data from the data base. The retrieval may be based on an index match between events and entries on a request and the structured data base.
L25 ANSWER 81 OF 88 BIOSIS COPYRIGHT 1998 BIOSIS	ACCESSION NUMBER: 85-314948 BIOSIS	INVENTOR(S): Bryan, Larry Wayne, Arlington, TX, United States	NUMBER	DATE	PATENT INFORMATION: ES 79-482374 790710	NUMBER	DATE
ACCESSION NUMBER:	85-314948 BIOSIS	Himmel, David Paul, Dallas, TX, United States	APPLICATION INFO.:	US 80-161448 800620 (6)	APPLICATION INFO.:	US 75-637511 751203 (5)	APPLICATION INFO.:
DOCUMENT NUMBER:	BA79-94944	Woster, Jr., George William, Dallas, TX, United	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:	Utility	DOCUMENT TYPE:
TITLE:	CLONING AND NUCLEOTIDE SEQUENCING OF THE GENES FOR	NUMBER OF CLAIMS: 6	EXEMPLARY CLAIM: 1	NUMBER OF DRAWINGS: 160 Drawing Figure(s); 144 Drawing Page(s)	LINE COUNT: 28817	NUMBER OF DRAWINGS: 160 Drawing Figure(s); 144 Drawing Page(s)	LINE COUNT: 28817

L25 ANSWER 85 OF 88 USPATFULL  
ACCESSION NUMBER: 76:5143 USPATFULL  
TITLE: Pulse generator for television for generating at least one pulse series having pulses of different duration and repetition period

INVENTOR(S): Kaptein, Eugenius Martinus, Eindhoven, Netherlands  
PATENT ASSIGNEE(S): U.S. Philips Corporation, New York, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 3935387 760127

APPLICATION INFO.: US 73-31984 730102 (5)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 71-122973, filed on 10 Mar 1971, now abandoned

NUMBER DATE

PRIORITY INFORMATION: NL 70-3669 700314

NL 70-7169 700516

NL 70-14884 701010

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Griffin, Robert L.

ASSISTANT EXAMINER: Sielar, George G.

LEGAL REPRESENTATIVE: Tifari, Frank R., Steckler, Henry J.

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 27 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 2589

AB A TV pulse generator for generating television synchronizing and blanking signals and a chrominance subcarrier gating signal. The switchable generator is formed with a clock pulse generator having a frequency which, for the CCIR and the RTMA standards, is 80 times the line frequency. In addition to auxiliary pulses of field flip-flops and pulse generators also generate auxiliary pulses of line frequency and of double the line frequency. The edges in the synchronizing and blanking signals and in the PAL or NTSC chrominance subcarrier gating signal generated by signal generators are accurately determined by trigger signals derived from the clock pulses.

L25 ANSWER 86 OF 88 USPATFULL  
ACCESSION NUMBER: 75:13464 USPATFULL  
TITLE: COMPOSITE THIN FILM OPTICAL DEVICE  
INVENTOR(S): Kamionow, Nan Paul, New Shrewsbury, NJ, United States  
Kogelnik, Hennig Werner, Fair Haven, NJ, United States  
PATENT ASSIGNEE(S): Bell Telephones Laboratories, Incorporated, Murray Hill, Berkeley Heights, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 3871742 750318

APPLICATION INFO.: US 73-407522 731018 (5)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Corbin, John K.

LEGAL REPRESENTATIVE: Canepa, L. C.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 336

AB The unclad faces of the substrates of two integrated-optics devices are butted together to form a composite structure having waveguiding layers on spaced-apart opposed surfaces. Diffraction gratings respectively associated with the layers are effective to cause a wave propagating in one layer to be diverted through the substrates and coupled to the other layer for propagation therein. If, for example, the first layer comprises an element of a modulator, both wave generation and modulation can be thereby carried out in a compact structure in an efficient way.

L25 ANSWER 87 OF 88 USPATFULL

ENTERED AT 10:02:37 ON 28 AUG 1998

FILE MEDLINE, CANCERLIT, SCISEARCH, BIOSIS, EMBASE, WPIDS,  
USPATFULL' ENTERED AT 10:02:54 ON 28 AUG 1998  
1 S 3122  
397502 ST(TICELL OR TW(LYMPHOCYTE OR THYMOCYTE  
1875287 S RECEPTOR

L1 1875 S CO-STIMULAT?

L5 1185 S L2 AND L3 AND L4

L6 5520103 S PROLIFERAT? OR ACTIVAT? OR DIVID? OR GROWTH

L7 194581 S ANTIGEN(B)SPECIF? OR ANTIGEN(B)TARGET?

L8 294 S L7 AND LB

L9 148 DUP REM L9 (86 DUPLICATES REMOVED)

L10 52 S L10 AND (NUCLEIC(W)ACID OR DNA OR CDNA OR GENE OR

L11 POLY

L12 4465 S (L2 AND L6) AND (NUCLEIC(W)ACID OR DNA OR CDNA OR

GE 2656 DUP REM L12 (1689 DUPLICATES REMOVED)

L13 666 S L3 AND EXTRACELL?

L14 53 S L0 AND EXTRACELL?

L15 46 DUP REM L15 (7 DUPLICATES REMOVED)

L16 41 S L11 AND (INTRACELL? OR CYTOPLASM?)

L17 48 S L11 AND (INTRACELL? OR CYTOPLASM?)

L18 44 S L11 AND LABEL?

L19 26 S L11 AND KIT

L20 637 S L13 AND KIT

L21 637 S L21 AND KIT

L22 313 S L21 AND EXTRACELL?

L23 92 S L13 AND VECTOR

L24 88 DUP REM L24 (4 DUPLICATES REMOVED)

=> logoff

ALL # QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y/N/HOLD): y

STN INTERNATIONAL LOGOFF AT 11:28:12 ON 28 AUG 1998

PATENT ASSIGNEE(S): Bessemer and Lake Erie Railway Company, BY SAID

Peterson, United States (U.S. corporation)

Quebec Cartier Mining, BY SAID

States (non-U.S. corporation)

United States Steel Corporation, BY SAID

Wardinsco, Joseph M., Lower Burrell, PA, United

States

PATENT ASSIGNEE(S): Bessemer and Lake Erie Railway Company, BY SAID

Peterson, United States (U.S. corporation)

Quebec Cartier Mining, BY SAID

States (non-U.S. corporation)

United States Steel Corporation, BY SAID

Wardinsco, Joseph M., Lower Burrell, PA, United

PATENT ASSIGNEE(S): Bessemer and Lake Erie Railway Company, BY SAID

Peterson, United States (U.S. corporation)

Quebec Cartier Mining, BY SAID

States (non-U.S. corporation)

United States Steel Corporation, BY SAID

Wardinsco, Joseph M., Lower Burrell, PA, United

PATENT ASSIGNEE(S): Bessemer and Lake Erie Railway Company, BY SAID

Peterson, United States (U.S. corporation)

Quebec Cartier Mining, BY SAID

States (non-U.S. corporation)

United States Steel Corporation, BY SAID

Wardinsco, Joseph M., Lower Burrell, PA, United

L1 7318040 730227

L2 71-178131710907 (5)

L3 Utility

L4 Primary Examiner: Woodward, Donald O.

L5 Legal Representative: Helm, Rea C.

L6 Number of Claims: 43

L7 Number of Drawings: 21 Drawing Figure(s); 11 Drawing Page(s)

L8 Line Count: 791

AB Method and apparatus for determining dynamic lateral and vertical wheel-rail forces. Axle bending sensors and axle load cells provide signals to a computer programmed to calculate lateral and vertical wheel-rail forces. These forces are used as the basis for comparing the effects of a variety of car truck design criteria and track conditions. Comparison of forces developed by the same equipment on different runs over the same trackage discloses track condition changes between runs.

=> d his

(FILE 'HOME' ENTERED AT 10:01:40 ON 28 AUG 1998)  
SET PLURALS ON

FILE 'MEDLINE, CANCERLIT, SCISEARCH, BIOSIS, WPIDS, USPATFULL'